前往化源商城

79902-63-9 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL646647
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2000
Volume: 43
Issue: 13
First Page: 2575
Last Page: 2585
DOI: 10.1021/jm0000564
Standard TypeStandard RelationStandard Value
LogD=-0.34
LogD=1.8
LogD=0.4
LogD=2.49
LogD=1.47
LogD=-2.66
LogD=-2.04
LogD=-1.24
LogD=-0.02
LogD=-0.08
LogD=0.35
LogD=-0.19
LogD=-0.02
LogD=-0.39
LogD=0.11
LogD=2.05
LogD=1.48
LogD=1.47
LogD=1.92
LogD=-1.34
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cytochrome P450 3A4
External ID: CHEMBL4479014
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2016
Volume: 26
Issue: 16
First Page: 4003
Last Page: 4006
DOI: 10.1016/j.bmcl.2016.06.088

Target ChEMBL ID: CHEMBL340
ChEMBL Target Name: Cytochrome P450 3A4
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
FC=1.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:
External ID: IucA Pilot Assay Tocris Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
0.98497.1319127496888TO1A04
1.004100.68831130342TO1A06
1.06110.646227253868TO1A07
1.023104.066889929465TO1A08
1.025104.422529784838TO1A09
1.032105.667269278644TO1A10
1.019103.355610218718TO1A11
1.059110.468407326181TO1A14
1.049108.690208049315TO1A15
1.044107.801108410883TO1A16
1.047108.334568193942TO1A17
1.054109.579307687748TO1A18
1.137124.338361685733TO1A19
1.109119.359403710509TO1A20
1.089115.803005156778TO1A21
1.097117.22556457827TO1A22
0.98998.0210123881216TO1B03
0.98296.7762728943157TO1B04
0.99298.5544721711813TO1B05
1.016102.822150435659TO1B06
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OPM1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011890.089787Complete curve; high efficacy-7.92922.47290.96942.5966132.6862-1.10 0 0 0 0 0 0 0 0 0 057.466123.2938140.8388112.24160.901644.089639.767736.478540.20639.176941.461857.466QC'd by ChemAxon
Cytotoxic0.417675.850987Complete curve; high efficacy-6.37921.53860.949872.4265148.2774-1.10 0 0 0 0 0 0 0 0 0 061.5626139.2774158.5971143.0204144.9664147.8567136.015191.815692.950575.674674.676861.5626QC'd by JohnsHopkins
Cytotoxic0.148294.419287Complete curve; high efficacy-6.82921.10.951759.4372153.8564-1.10 0 0 0 0 0 0 0 0 0 055.0456164.8354134.704151.2303143.6834134.761595.648470.062167.305676.105555.692455.0456QC'd by Selleck
Cytotoxic0.166394.102386Complete curve; high efficacy-6.77922.72020.972950.0751144.1775-1.10 0 0 0 0 0 0 0 0 0 056.0568132.0924142.9387160.1371137.1338142.289985.893148.200245.041752.603354.183256.0568QC'd by ACC
Cytotoxic0.0332121.075286Complete curve; high efficacy-7.479210.984142.1192163.1944-1.10 0 0 0 0 0 0 0 0 0 035.7472158.2854158.4708139.505123.340671.574165.258955.071850.086742.178237.195535.7472QC'd by Selleck
Cytotoxic0.742778.671685Complete curve; high efficacy-6.12921.88510.983463.6148142.2865-1.10 0 0 0 0 0 0 0 0 0 058.2475142.1116146.4992135.5304145.8795136.7066141.0466113.833174.38665.128871.886858.2475QC'd by Tocris
Cytotoxic0.833386.219185Complete curve; high efficacy-6.079210.930267.549153.7681-1.10 0 0 0 0 0 0 0 0 0 069.8532158.4753142.7847153.7541141.7507166.925141.693105.2958104.667477.221776.165269.8532QC'd by Tocris
Cytotoxic3.722164.493585Complete curve; high efficacy-5.42924.95490.792112.0642176.5577-1.10 0 0 0 0 0 0 0 0 0 089.6942158.9633166.2699180.3984167.1951174.9654191.2964181.3214193.1909122.0222135.538889.6942QC'd by Tocris
Cytotoxic0.0526123.236885Complete curve; high efficacy-7.27920.60.972433.4065156.6433-1.10 0 0 0 0 0 0 0 0 0 035.7651153.6951126.1364142.4363103.249192.595173.147860.614343.388740.031337.882135.7651QC'd by Tocris
Cytotoxic0.006677.526284Complete curve; high efficacy-8.17920.80.975321.696999.2231-1.10 0 0 0 0 0 0 0 0 0 013.262791.55276.413756.561242.193434.028331.180927.350626.077820.634320.214413.2627QC'd by Tocris
Cytotoxic0.5258123.459984Complete curve; high efficacy-6.27921.39870.968242.1223165.5821-1.10 0 0 0 0 0 0 0 0 0 025.7016164.86160.7689152.0063170.1205168.2257149.303488.213874.069651.798249.790125.7016QC'd by JohnsHopkins
Cytotoxic1.865582.375984Complete curve; high efficacy-5.72922.33320.929161.702144.078-1.10 0 0 0 0 0 0 0 0 0 051.7606136.01140.2451152.6106148.0124143.6336147.0904134.4052111.284254.479484.371251.7606QC'd by Selleck
Cytotoxic2.3485101.924784Complete curve; high efficacy-5.62920.60.955871.9549173.8795-1.10 0 0 0 0 0 0 0 0 0 091.649176.6761171.0851177.7813159.9071159.3009150.4576153.7054126.8633116.427184.815491.649QC'd by SynKinase
Cytotoxic0.018790.923784Complete curve; high efficacy-7.72920.70.995926.7347117.6584-1.10 0 0 0 0 0 0 0 0 0 029.5723109.5774101.759683.749673.379952.652141.5735.435430.241226.675925.387729.5723QC'd by Microsource
Cytotoxic0.0132127.373583Complete curve; high efficacy-7.87920.70.972217.3385144.712-1.10 0 0 0 0 0 0 0 0 0 033.7384132.8301113.247589.341775.717555.400227.741422.107814.440214.011616.778533.7384QC'd by Tocris
Cytotoxic3.722186.014283Complete curve; high efficacy-5.42921.210.972165.5416151.5558-1.10 0 0 0 0 0 0 0 0 0 066.7748154.8648146.5307153.6238147.9405153.7843144.2907154.4262119.8728100.256583.011166.7748QC'd by Tocris
Cytotoxic0.3722105.789883Complete curve; high efficacy-6.42922.84730.98436.148141.9378-1.10 0 0 0 0 0 0 0 0 0 022.8052141.9378142.9518145.1156141.0583137.6217130.508557.913351.266941.388233.000722.8052QC'd by JohnsHopkins
Cytotoxic1.6626102.314483Complete curve; high efficacy-5.779210.924240.9668143.2813-1.10 0 0 0 0 0 0 0 0 0 047.0105152.3961124.7264140.9824142.6059141.9566147.0368112.397281.287385.089138.460247.0105QC'd by Microsource
Cytotoxic0.0118140.01383Complete curve; high efficacy-7.92922.58840.998217.9926158.0057-1.10 0 0 0 0 0 0 0 0 0 014.8749156.5885154.4434130.9445.126815.310417.374218.814419.415621.188621.270814.8749QC'd by Selleck
Cytotoxic0.4686118.608983Complete curve; high efficacy-6.32921.85790.987228.1061146.7151-1.10 0 0 0 0 0 0 0 0 0 027.0205138.0525155.3457144.6536140.3247148.8544132.291370.355346.41333.133522.075327.0205QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OC1MY5-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.016675.705499Complete curve; high efficacy-7.77921.62590.8287113.3664189.0718-1.10 0 0 0 0 0 0 0 0 0 076.415189.0718184.1323176.4162143.7765121.3848112.8196136.1769124.1622121.4205110.84976.415QC'd by SigmaAldrich
Cytotoxic0.014878.323895Complete curve; high efficacy-7.82921.88510.884990.161168.4848-1.10 0 0 0 0 0 0 0 0 0 067.4943179.706152.1469156.7226115.95190.887181.242794.0684108.643892.5891100.356267.4943QC'd by BIOMOL
Cytotoxic0.0093193.289593Complete curve; high efficacy-8.02920.50.866672.6851265.9745-1.10 0 0 0 0 0 0 0 0 0 0105.1458244.5929174.7663172.838154.9069132.1222117.372990.589987.865585.670530.7772105.1458QC'd by Microsource
Cytotoxic0.0021162.783989Complete curve; high efficacy-8.67922.25260.909541.4972204.2812-1.10 0 0 0 0 0 0 0 0 0 016.0569187.9512112.283154.611932.400643.04248.563547.468974.45340.548125.593516.0569QC'd by Tocris
Cytotoxic0.0037168.183989Complete curve; high efficacy-8.42921.98870.95444.8326213.0165-1.10 0 0 0 0 0 0 0 0 0 016.7704206.3802163.409786.454636.022349.839739.359743.293852.688461.372857.854816.7704QC'd by Waterstone
Cytotoxic0.0469148.810689Complete curve; high efficacy-7.32922.40640.8561.7336210.5442-1.10 0 0 0 0 0 0 0 0 0 08.2046222.3206202.2319203.978192.1974118.262335.92446.047760.9187116.720798.87498.2046QC'd by ChemAxon
Cytotoxic0.0026113.270989Complete curve; high efficacy-8.57923.1320.897742.9988156.2697-1.10 0 0 0 0 0 0 0 0 0 021.2361152.3367113.413840.593638.127740.362443.602334.137943.871364.736864.064821.2361QC'd by Tocris
Cytotoxic0.0017114.495389Complete curve; high efficacy-8.77924.0950.841643.8532158.3484-1.10 0 0 0 0 0 0 0 0 0 014.1898152.803967.85254.519352.359357.345849.82462.059347.505430.836728.465514.1898QC'd by Selleck
Cytotoxic0.002672.734289Complete curve; high efficacy-8.57922.72020.907441.83114.5643-1.10 0 0 0 0 0 0 0 0 0 049.3766112.187583.595146.53530.954733.435532.312943.245244.089344.797856.003549.3766QC'd by Microsource
Cytotoxic0.0743128.224189Complete curve; high efficacy-7.12920.30.807365.0905193.3146-1.10 0 0 0 0 0 0 0 0 0 071.5247186.4209158.6743129.1227120.8146138.5824133.4969104.1228120.2992101.960377.775671.5247QC'd by Tocris
Cytotoxic0.0662125.720489Complete curve; high efficacy-7.17921.82650.971967.5385193.259-1.10 0 0 0 0 0 0 0 0 0 052.5197186.6163181.5655200.1337192.1342128.241283.363287.409864.631570.685465.116152.5197QC'd by SantaCruz Bio
Cytotoxic0.661978.285988Complete curve; high efficacy-6.17921.88510.946996.3016174.5875-1.10 0 0 0 0 0 0 0 0 0 0101.3711171.7651176.8613184.4702181.7039154.2237171.0284143.1726100.579190.9185104.0348101.3711QC'd by BIOMOL
Cytotoxic0.0935125.731288Complete curve; high efficacy-7.02923.990.970262.9518188.683-1.10 0 0 0 0 0 0 0 0 0 071.3789173.2237176.4213202.4283200.5745169.056972.067947.835455.511865.182873.840471.3789QC'd by Selleck
Cytotoxic0.0743119.127488Complete curve; high efficacy-7.12920.70.98858.8412177.9686-1.10 0 0 0 0 0 0 0 0 0 065.4007172.7284171.0856155.1599146.3776116.585999.779291.984365.419864.002856.279365.4007QC'd by Axon Medchem
Cytotoxic0.3317103.910288Complete curve; high efficacy-6.47920.30.843677.4858181.396-1.10 0 0 0 0 0 0 0 0 0 0101.3477161.302177.473153.8803133.2684139.1275144.3925135.8497117.608691.5334104.8313101.3477QC'd by Tocris
Cytotoxic0.1321123.71788Complete curve; high efficacy-6.879210.962367.9127191.6297-1.10 0 0 0 0 0 0 0 0 0 045.8939178.5371199.9241184.0193181.5655149.5884112.02994.762981.731373.616983.205245.8939QC'd by Microsource
Cytotoxic0.0066144.59188Complete curve; high efficacy-8.17922.72020.931843.5813188.1723-1.10 0 0 0 0 0 0 0 0 0 07.9675169.8483200.8523105.256949.605442.518545.303152.145650.632956.794649.51437.9675QC'd by SIGMA
Cytotoxic0.935111.476387Complete curve; high efficacy-6.02921.46410.907288.9886200.4649-1.10 0 0 0 0 0 0 0 0 0 065.9282174.089200.6763211.7975212.4609203.6327185.8171171.8065108.7421105.1811115.181865.9282QC'd by Selleck
Cytotoxic0.0118148.747387Complete curve; high efficacy-7.92921.88510.914741.9403190.6876-1.10 0 0 0 0 0 0 0 0 0 08.0822198.2962171.9006154.032174.692245.681859.094162.628163.424350.903813.29568.0822QC'd by Selleck
Cytotoxic1.662684.625787Complete curve; high efficacy-5.77922.72020.9593106.2986190.9242-1.10 1 0 0 0 0 0 0 0 0 0104.8088197.9176147.6744188.5439182.4788196.4457175.6724199.742148.305107.0547110.4851104.8088QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS_34-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.041888.877985Complete curve; high efficacy-7.37921.210.83931.4966120.3746-1.10 0 0 0 0 0 0 0 0 0 07.7124132.8926100.448796.9022107.952767.422923.232138.254730.074155.763343.34537.7124QC'd by ChemAxon
Cytotoxic0.0148116.450385Complete curve; high efficacy-7.82920.40.883227.623144.0733-1.10 0 0 0 0 0 0 0 0 0 023.9089133.149384.985690.676488.203880.547548.934346.794939.846148.370238.326523.9089QC'd by Tocris
Cytotoxic0.00363.507484Complete curve; high efficacy-8.52921.24750.846222.061585.5689-1.10 0 0 0 0 0 0 0 0 0 04.685578.444856.901238.37827.125924.86230.850833.175427.356122.258211.85044.6855QC'd by AG Scientific
Cytotoxic0.066281.534784Complete curve; high efficacy-7.17920.50.935226.2812107.8158-1.10 0 0 0 0 0 0 0 0 0 041.7013104.6491.691185.710374.992566.250263.828947.143640.11632.645316.398141.7013QC'd by Microsource
Cytotoxic0.005388.857983Complete curve; high efficacy-8.27920.70.918715.3166104.1745-1.10 0 0 0 0 0 0 0 0 0 017.273995.7755.043766.176737.487330.62723.923816.028919.552917.45899.815517.2739QC'd by Toronto Research
Cytotoxic0.209387.781383Complete curve; high efficacy-6.67923.06540.98628.7833116.5646-1.10 0 0 0 0 0 0 0 0 0 028.0348105.4018124.2663111.216120.9286117.829382.793730.938430.822427.522130.01228.0348QC'd by ACC
Cytotoxic0.016684.33283Complete curve; high efficacy-7.77922.72020.984217.1644101.4964-1.10 0 0 0 0 0 0 0 0 0 016.809492.1572111.714893.822544.879723.29116.702114.931216.05218.314117.449816.8094QC'd by ChemAxon
Cytotoxic0.037278.620483Complete curve; high efficacy-7.42922.58840.984618.797997.4182-1.10 0 0 0 0 0 0 0 0 0 012.888592.420695.8169102.935482.036534.503824.164219.157513.771216.322226.468312.8885QC'd by Selleck
Cytotoxic1.04996.497783Complete curve; high efficacy-5.97920.50.957536.2422132.7399-1.10 0 0 0 0 0 0 0 0 0 054.2766130.3979127.8742134.2077109.0067109.1952107.713199.92678.571159.936952.628454.2766QC'd by LINCS
Cytotoxic0.0469113.5983Complete curve; high efficacy-7.32921.92820.977620.8655134.4556-1.10 0 0 0 0 0 0 0 0 0 021.4008136.3735118.7418147.5619108.852467.204221.009224.201124.538819.698820.300321.4008QC'd by Tocris
Cytotoxic0.0059134.11483Complete curve; high efficacy-8.22920.90.958214.3732148.4872-1.10 0 0 0 0 0 0 0 0 0 07.7187135.6994.255592.291235.67427.57326.610323.447918.96313.139211.28037.7187QC'd by Selleck
Cytotoxic0.016682.99983Complete curve; high efficacy-7.77924.44950.914818.7882101.7872-1.10 0 0 0 0 0 0 0 0 0 01.306589.3692109.2888105.280939.259712.56078.63117.245227.937241.290725.02181.3065QC'd by BIOMOL
Cytotoxic0.0026124.131382Complete curve; high efficacy-8.57921.47810.986411.3246135.4559-1.10 0 0 0 0 0 0 0 0 0 014.9487124.278272.55539.097213.763318.160410.303510.566110.76498.90756.618214.9487QC'd by Tocris
Cytotoxic0.0209112.54382Complete curve; high efficacy-7.67921.96730.932614.5764127.1195-1.10 0 0 0 0 0 0 0 0 0 00.7959123.8363116.6866132.122462.186831.22417.327713.62456.960345.1415.10240.7959QC'd by NCGCChem
Cytotoxic0.104980.762282Complete curve; high efficacy-6.97923.990.931416.214996.9771-1.10 0 0 0 0 0 0 0 0 0 02.1195101.382375.2262112.248999.869687.632124.000528.457125.40816.87938.90662.1195QC'd by ChemAxon
Cytotoxic0.234892.655582Complete curve; high efficacy-6.62920.90.986616.7612109.4167-1.10 0 0 0 0 0 0 0 0 0 013.3983112.307799.4639110.160599.618592.250163.412843.116934.989225.203720.221113.3983QC'd by JohnsHopkins
Cytotoxic0.0264105.223682Complete curve; high efficacy-7.57922.78680.988110.1409115.3645-1.10 0 0 0 0 0 0 0 0 0 05.3828108.8197112.7123124.379475.066919.974411.747517.45588.74528.59417.9615.3828QC'd by Selleck
Cytotoxic0.93588.261382Complete curve; high efficacy-6.02921.78850.855620.4336108.6949-1.10 0 0 0 0 0 0 0 0 0 04.852785.5635121.1104117.096194.650799.9913137.032269.811848.833229.794829.96994.8527QC'd by Selleck
Cytotoxic0.0059119.868782Complete curve; high efficacy-8.22920.90.98910.4647130.3334-1.10 0 0 0 0 0 0 0 0 0 09.7544119.720688.055968.561935.492830.376516.190110.80912.106211.21728.0079.7544QC'd by Tocris
Cytotoxic0.4176152.652182Complete curve; high efficacy-6.37920.40.9686-18.9995133.6526-1.10 0 0 0 0 0 0 0 0 0 02.9146127.427102.6532123.629693.093583.859362.24155.771444.320918.43846.1372.9146QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_L363-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011864.8887Complete curve; high efficacy-7.92923.990.906542.9911107.8711-1.10 0 0 0 0 0 0 0 0 0 175.9379117.166298.059101.666744.543237.931551.79645.54545.89855.696524.21575.9379QC'd by ChemAxon
Cytotoxic0.001086Complete curve; high efficacy-900.8727.00327.003-1.10 0 0 0 0 0 0 0 0 0 011.714116.109651.782338.477438.14932.576327.00321.712513.65628.24944.831811.714QC'd by Tocris
Cytotoxic0.014887.3385Complete curve; high efficacy-7.82922.72020.839428.2225115.5525-1.10 0 0 0 0 0 0 0 0 0 02.7164112.6565118.5558105.208650.461432.896456.123844.203245.685613.05273.96712.7164QC'd by ChemAxon
Cytotoxic0.074381.047985Complete curve; high efficacy-7.12922.40640.987736.057117.1048-1.10 0 0 0 0 0 0 0 0 0 036.612118.1815112.941121.7674108.916987.133342.59131.000532.05139.154343.592636.612QC'd by Selleck
Cytotoxic0.013295.183485Complete curve; high efficacy-7.87922.58840.978930.3117125.4951-1.10 0 0 0 0 0 0 0 0 0 022.3434119.5176131.0238109.768849.199641.232339.094429.184232.449924.950225.888622.3434QC'd by Tocris
Cytotoxic0.037296.952684Complete curve; high efficacy-7.42923.67720.943926.3959123.3485-1.10 0 0 0 0 0 0 0 0 0 020.4921101.7407120.2132147.5217112.769437.937439.317124.381225.076727.694220.417320.4921QC'd by Selleck
Cytotoxic0.1147102.026284Complete curve; high efficacy-6.94040.40.945728.8277130.8539-1.10 0 0 0 0 0 0 0 0 0 1108.0014122.9006125.5314115.924689.870995.612875.420675.658466.669245.064945.6837108.0014QC'd by Selleck
Cytotoxic0.009390.158484Complete curve; high efficacy-8.02921.71370.962524.1405114.2989-1.10 0 0 0 0 0 0 0 0 0 020.1633106.7519116.404475.80742.460431.644837.517319.116617.345730.109618.866820.1633QC'd by NCGCChem
Cytotoxic0.468669.609184Complete curve; high efficacy-6.32921.69240.827647.7156117.3247-1.10 0 0 0 0 0 0 0 0 0 195.324899.0689105.4815112.5472134.071139.294895.863678.07556.20561.315734.97695.3248QC'd by Microsource
Cytotoxic0.295785.225883Complete curve; high efficacy-6.52924.95490.905530.0023115.2281-1.10 0 0 0 0 0 0 0 0 1 045.1208102.1961108.7224107.4279107.404145.4631114.174621.348922.64833.189677.55645.1208QC'd by NCGCChem
Cytotoxic0.0118107.387883Complete curve; high efficacy-7.92924.44950.994618.1514125.5392-1.10 0 0 0 0 0 0 0 0 0 1103.6539130.2388120.1313117.134124.788321.804212.746820.289419.91221.366715.3748103.6539QC'd by Selleck
Cytotoxic0.033278.333383Complete curve; high efficacy-7.47924.44950.957520.808999.1422-1.10 0 0 0 0 0 0 0 0 0 1105.677694.56286.401118.767388.388324.521523.716318.859423.322922.567716.9857105.6776QC'd by Chemscene
Cytotoxic0.011886.29183Complete curve; high efficacy-7.92920.910.971220.4028106.6938-1.10 0 0 0 0 0 0 0 0 0 013.990798.3598100.650970.772445.884940.959433.218425.044519.165723.31217.822613.9907QC'd by Selleck
Cytotoxic0.234884.542283Complete curve; high efficacy-6.62921.10.954725.2427109.7849-1.10 0 0 0 0 0 0 0 0 0 1114.3833102.02113.1558103.8422121.074381.328372.684251.920531.812126.372328.0582114.3833QC'd by ChemieTek
Cytotoxic0.014886.1283Complete curve; high efficacy-7.82922.18760.972516.3085102.4286-1.10 0 0 0 0 0 0 0 0 0 07.9507102.926198.733390.777842.92222.299723.200730.230611.653910.657913.08247.9507QC'd by Selleck
Cytotoxic0.148277.093883Complete curve; high efficacy-6.82924.95490.955322.412899.5066-1.10 0 0 0 0 0 0 0 0 0 09.87102.096792.544998.652790.3526113.472742.025228.643431.5424.979314.77199.87QC'd by Chemscene
Cytotoxic0.417691.373683Complete curve; high efficacy-6.37921.69240.985829.7282121.1017-1.10 0 1 0 0 0 0 0 0 0 021.3801116.2452129.3034186.5441118.5918113.5565105.088162.785435.762934.74535.353721.3801QC'd by Selleck
Cytotoxic1.04987.361683Complete curve; high efficacy-5.979210.877236.1973123.5589-1.10 0 0 0 0 0 0 0 0 0 054.1491117.4289109.6638131.7472129.0154136.577793.933688.945583.642543.457225.12354.1491QC'd by SynKinase
Cytotoxic0.1482113.990583Complete curve; high efficacy-6.82921.28760.888823.8075137.7981-1.10 0 0 0 0 0 0 0 0 0 08.0453114.2505119.5624176.2421137.6679106.682559.028455.250738.182324.837127.40678.0453QC'd by Tocris
Cytotoxic1.17785.496383Complete curve; high efficacy-5.92923.62720.914939.2135124.7097-1.10 0 0 0 0 0 0 0 0 0 027.6517113.2381135.3021111.0564135.5045142.3677111.5001118.811556.830633.204257.637227.6517QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OCIMY7-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0148138.417292Complete curve; high efficacy-7.82920.80.985473.4473211.8645-1.10 0 0 0 0 0 0 0 0 0 076.0615206.4576176.3477160.675143.036102.215687.458676.386675.942381.513271.284576.0615QC'd by Selleck
Cytotoxic0.1865129.709492Complete curve; high efficacy-6.72922.47290.9102104.5908234.3002-1.10 0 0 0 0 0 0 0 0 0 097.9499212.7695199.584247.0735277.3731227.6905162.5507123.8591102.5004104.1059104.398997.9499QC'd by SantaCruz Bio
Cytotoxic0.525872.960991Complete curve; high efficacy-6.27922.72020.9263121.6641194.625-1.10 0 0 0 0 0 0 0 0 0 1182.846196.2276201.2704206.5478177.6678187.1047193.8819153.4274124.7553110.5225133.7805182.846QC'd by SIGMA
Cytotoxic0.0469134.726691Complete curve; high efficacy-7.32922.33320.942779.2711213.9977-1.10 0 0 0 0 0 0 0 0 0 074.524225.8348183.7696233.1661192.207130.243974.8439101.457875.21388.15864.064774.524QC'd by Selleck
Cytotoxic0.001091Complete curve; high efficacy-900.973648.780348.7803-1.10 0 0 0 0 0 0 0 0 0 047.83166.158106.533567.344835.203147.280344.656348.780346.703651.704556.888247.83QC'd by Tocris
Cytotoxic0.001090Complete curve; high efficacy-900.820746.422646.4226-1.10 0 0 0 0 0 0 0 0 0 05.4032205.1041113.398945.042360.965955.970682.491946.422618.259210.66488.46975.4032QC'd by Tocris
Cytotoxic1.481867.805689Complete curve; high efficacy-5.82924.95490.7621141.433209.2386-1.10 0 0 0 0 0 0 0 0 0 0116.0869187.3686222.298199.2101217.5801185.2508221.0682234.3031161.6854158.4572150.9575116.0869QC'd by ChemAxon
Cytotoxic0.001089Complete curve; high efficacy-900.959138.870638.8706-1.10 0 0 0 0 0 0 0 0 0 039.1109165.4745147.989392.122638.870647.652815.964314.55779.16457.80787.070839.1109QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.938841.142141.1421-1.10 0 0 0 0 0 0 0 0 0 03.8961184.0933141.73391.783118.669184.427141.142140.416126.249718.52235.72733.8961QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.988840.837940.8379-1.11 0 0 0 0 0 0 0 0 0 026.1407121.6554195.8384155.511388.106368.094737.765640.837940.099127.971631.77326.1407QC'd by Selleck
Cytotoxic0.038292.573488Complete curve; high efficacy-7.4180.40.889752.7945145.3679-1.10 0 0 0 0 0 0 0 0 0 051.9291116.2057136.3435103.092491.965479.473982.026983.101367.37361.55557.499951.9291QC'd by ChemPacific
Cytotoxic0.0743134.535488Complete curve; high efficacy-7.12921.210.930757.9113192.4467-1.10 0 0 0 0 0 0 0 0 0 049.7147175.8519207.2976185.8686162.8742143.048663.049199.107467.380557.937949.251549.7147QC'd by ChemAxon
Cytotoxic0.001088Complete curve; high efficacy-900.875833.721233.7212-1.10 0 0 0 0 0 0 0 0 0 04.1324152.461297.589368.749932.264258.815947.257833.72128.80494.81863.54334.1324QC'd by Microsource
Cytotoxic3.722185.223987Complete curve; high efficacy-5.42924.95490.891150.0271235.251-1.11 0 0 0 0 0 0 0 0 0 0154.7033204.9209231.691212.9559243.8102227.9286234.025230.2626264.0915159.589149.6383154.7033QC'd by SIGMA
Cytotoxic1.3207106.100387Complete curve; high efficacy-5.87921.82650.9417105.4088211.509-1.10 0 0 0 0 0 0 0 0 0 0114.0374223.8378192.8578196.2457228.3532212.5214209.5506192.8647146.6919120.128291.3668114.0374QC'd by XcessBio
Cytotoxic0.1482151.498787Complete curve; high efficacy-6.82920.70.9856.0265207.5252-1.10 1 0 0 0 0 0 0 0 0 051.814202.2596122.7624197.3713167.7834153.3308139.098485.59679.140368.517869.503551.814QC'd by Selleck
Cytotoxic0.093570.605687Complete curve; high efficacy-7.02924.50450.961352.9846123.5901-1.10 1 0 0 0 0 0 0 0 0 041.374115.1832175.7294133.236122.1014112.51554.255357.095263.733753.56750.781741.374QC'd by SynKinase
Cytotoxic0.001087Complete curve; high efficacy-900.957630.251130.2511-1.10 0 0 0 0 0 0 0 0 0 07.7137142.2621159.750441.789140.52422.573521.992937.056330.251115.915614.28657.7137QC'd by Selleck
Cytotoxic0.001087Complete curve; high efficacy-900.935330.652530.6525-1.10 0 0 0 0 0 0 0 0 0 010.0983153.490588.457756.636528.973143.343733.830730.652518.384511.756211.590310.0983QC'd by Selleck
Cytotoxic0.2635171.464186Complete curve; high efficacy-6.57924.95490.90355.2524226.7165-1.10 0 0 0 0 0 0 0 0 0 087.6192224.0953196.7275198.1303295.2794221.4309194.687546.556551.514833.151858.588387.6192QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM1R-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0093104.652788Complete curve; high efficacy-8.02921.96730.994643.2871147.9397-1.10 0 0 0 0 0 0 0 0 0 046.9856151.2515136.3124112.156860.347441.289143.600645.536740.858441.487544.24846.9856QC'd by Cayman
Cytotoxic0.052690.729187Complete curve; high efficacy-7.27921.24750.96949.3002140.0293-1.10 0 0 0 0 0 0 0 0 0 036.2116136.8931136.6639140.7519111.565496.338258.16355.06458.665957.368148.852936.2116QC'd by Selleck
Cytotoxic0.1865111.099886Complete curve; high efficacy-6.72921.55790.959758.0636169.1634-1.10 0 0 0 0 0 0 0 0 0 030.8392165.6134164.7399166.9572172.8379153.7472111.421772.293771.432370.561564.820230.8392QC'd by Tocris
Cytotoxic0.104999.253786Complete curve; high efficacy-6.97923.1320.878851.4415150.6952-1.10 0 0 0 0 0 0 0 0 0 04.3763133.6762159.094152.6324154.4225134.385464.985170.629468.541858.555955.58134.3763QC'd by Selleck
Cytotoxic0.331794.992984Complete curve; high efficacy-6.47920.30.952137.641132.6338-1.10 0 0 0 0 0 0 0 0 0 050.4436114.4568123.9845113.833196.15292.162489.666481.881579.922468.155859.613750.4436QC'd by Tocris
Cytotoxic0.742784.904484Complete curve; high efficacy-6.12922.25260.93345.6644130.5688-1.10 0 0 0 0 0 0 0 0 0 036.4643134.3384115.1991125.3701119.0101144.1666143.817297.989150.782553.051854.389936.4643QC'd by Tocris
Cytotoxic0.833375.35484Complete curve; high efficacy-6.07923.990.961446.5835121.9376-1.10 0 0 0 0 0 0 0 0 0 033.0973124.2208119.0164110.2614120.2463126.3612130.9298108.885950.932550.258656.053633.0973QC'd by Selleck
Cytotoxic0.372288.076284Complete curve; high efficacy-6.42924.44950.970337.6549125.7311-1.10 0 0 0 0 0 0 0 0 0 044.0074106.5992127.2247130.6238138.3415127.8948120.698748.218435.913536.364134.92644.0074QC'd by Selleck
Cytotoxic0.0093130.642584Complete curve; high efficacy-8.02920.90.986724.621155.2635-1.10 0 0 0 0 0 0 0 0 0 018.1076143.3641125.709898.568566.033436.988237.469536.872131.027325.006419.273518.1076QC'd by Toronto Research
Cytotoxic0.468684.349983Complete curve; high efficacy-6.32923.06540.892737.763122.1129-1.10 0 0 0 0 0 0 0 0 0 08.9174100.9718133.1095113.0152128.6977133.2765119.584364.278453.378148.528644.758.9174QC'd by SynKinase
Cytotoxic0.331788.677483Complete curve; high efficacy-6.47921.62590.990934.1483122.8257-1.10 0 0 0 0 0 0 0 0 0 032.8455112.8257122.9968126.477124.3559121.535296.460460.397143.403334.092232.873332.8455QC'd by JohnsHopkins
Cytotoxic0.2957104.439583Complete curve; high efficacy-6.52920.60.963633.4657137.9052-1.10 0 0 0 0 0 0 0 0 0 030.41139.5422127.9789115.7906133.779110.19387.959673.595558.104955.361347.914130.41QC'd by JohnsHopkins
Cytotoxic2.348586.675883Complete curve; high efficacy-5.62924.0950.968453.6121140.2879-1.10 0 0 0 0 0 0 0 0 0 051.2528135.5146146.9511127.3268148.5202130.0159143.2286148.4195122.370157.612755.742751.2528QC'd by LINCS
Cytotoxic0.589978.481583Complete curve; high efficacy-6.229210.96239.6422118.1236-1.10 0 0 0 0 0 0 0 0 0 036.8849113.0988105.5924123.1519126.3882114.847893.448478.396461.99652.62141.616136.8849QC'd by NCGCChem
Cytotoxic1.662685.967283Complete curve; high efficacy-5.77922.47290.929540.7279126.6952-1.10 0 0 0 0 0 0 0 0 0 028.4756118.8121112.7597122.0662124.4452131.3159149.7541122.838280.294449.812550.994128.4756QC'd by Microsource
Cytotoxic0.074390.741383Complete curve; high efficacy-7.12921.96730.946425.6492116.3905-1.10 0 0 0 0 0 0 0 0 0 05.9198106.5785111.2723128.5693109.673979.414437.115833.672241.61829.688719.14745.9198QC'd by Selleck
Cytotoxic0.4176196.850483Complete curve; high efficacy-6.37920.30.9606-31.7676165.0828-1.10 0 0 0 0 0 0 0 0 0 02.8348135.921148.6439123.1507111.473178.544671.308564.760262.7228.685414.04622.8348QC'd by Microsource
Cytotoxic0.525895.995583Complete curve; high efficacy-6.27920.40.975335.9633131.9588-1.10 0 0 0 0 0 0 0 0 0 050.6988124.3759129.0401111.2096110.666498.319199.274582.50577.957559.853253.136550.6988QC'd by Microsource
Cytotoxic0.1865153.297482Complete curve; high efficacy-6.72920.40.9838-19.1976134.0998-1.10 0 0 0 0 0 0 0 0 0 01.5971128.3939102.50195.957690.349376.112759.654643.641425.05494.92791.71.5971QC'd by NCGCChem
Cytotoxic0.4686112.636982Complete curve; high efficacy-6.32920.70.96616.772129.4089-1.10 0 0 0 0 0 0 0 0 0 013.877117.2722122.3984135.2437130.0817105.741580.360967.039351.753440.54130.169413.877QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-mm1s-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.013278.888888Complete curve; high efficacy-7.87923.51170.995147.2347126.1235-1.10 0 0 0 0 0 0 0 0 0 042.2827127.6613122.708120.202461.112651.288545.516147.740746.357847.533948.054342.2827QC'd by SigmaAldrich
Cytotoxic0.018794.499187Complete curve; high efficacy-7.72921.96730.992343.1973137.6963-1.10 0 0 0 0 0 0 0 0 0 047.5181141.319129.8171127.504186.807649.094247.049942.27740.938537.815144.862147.5181QC'd by ACC
Cytotoxic0.525873.986887Complete curve; high efficacy-6.27921.53860.960875.2185149.2053-1.10 0 0 0 0 0 0 0 0 0 066.1566142.7053154.8249147.903146.0134146.4254144.006104.273988.096990.959471.649566.1566QC'd by JohnsHopkins
Cytotoxic0.0059140.454587Complete curve; high efficacy-8.22921.41630.968736.1127176.5672-1.10 0 0 0 0 0 0 0 0 0 010.8624168.6765147.515496.349154.200241.544537.572842.209341.742240.483343.494610.8624QC'd by Cayman
Cytotoxic0.013279.744487Complete curve; high efficacy-7.87920.60.898641.6151121.3595-1.10 0 0 0 0 0 0 0 0 0 026.1462113.0499103.137682.203181.485258.693853.314553.669254.537937.118656.47926.1462QC'd by SigmaAldrich
Cytotoxic0.166378.942786Complete curve; high efficacy-6.77923.92950.945949.4968128.4395-1.10 0 0 0 0 0 0 0 0 0 039.1638119.9619118.7114121.8873145.134135.660277.501949.371642.704855.488760.915639.1638QC'd by SynKinase
Cytotoxic0.117799.522986Complete curve; high efficacy-6.92920.50.978453.5004153.0233-1.10 0 0 0 0 0 0 0 0 0 054.2364146.2425146.4285127.5196118.6607112.3725102.003786.351770.597462.725470.168354.2364QC'd by Selleck
Cytotoxic0.234879.922286Complete curve; high efficacy-6.62921.46410.979158.9416138.8638-1.10 0 0 0 0 0 0 0 0 0 062.4132143.4278135.9313129.1028144.3799129.2524105.203973.502570.461953.739757.639662.4132QC'd by BIOMOL
Cytotoxic0.0187133.261986Complete curve; high efficacy-7.72920.60.944135.7906169.0525-1.10 0 0 0 0 0 0 0 0 0 027.5582156.1894139.4018135.437491.108661.224166.094967.717153.596142.584230.965227.5582QC'd by Toronto Research
Cytotoxic0.029679.81285Complete curve; high efficacy-7.52923.1320.836730.4945110.3065-1.10 0 0 0 0 0 0 0 0 0 0-0.421991.4427118.502121.280287.417839.0630.378326.00428.811631.88664.9696-0.4219QC'd by ChemAxon
Cytotoxic0.468672.558485Complete curve; high efficacy-6.32921.47810.89858.4082130.9666-1.10 0 0 0 0 0 0 0 0 0 036.5241121.5091138.67123.1995141.6082124.8321119.084385.203570.543862.760678.203936.5241QC'd by SIGMA
Cytotoxic0.574989.317185Complete curve; high efficacy-6.24043.51170.938153.4216142.7387-1.10 0 0 0 0 0 0 0 0 0 042.1397122.2594133.5752138.8262155.9137150.9759155.3277133.833270.150756.140464.45942.1397QC'd by Selleck
Cytotoxic0.104990.112685Complete curve; high efficacy-6.97921.10.9642.4601132.5727-1.10 0 0 0 0 0 0 0 0 0 048.0597134.7202138.2028122.4795111.2704105.46677.884945.23345.497230.823755.272548.0597QC'd by Tocris
Cytotoxic0.041880.357885Complete curve; high efficacy-7.37920.60.851133.6315113.9892-1.10 0 0 0 0 0 0 0 0 0 011.0841101.2736106.771596.716682.13570.480940.105551.505451.453654.137541.943611.0841QC'd by Microsource
Cytotoxic0.661994.77385Complete curve; high efficacy-6.17921.47810.980353.7716148.5446-1.10 0 0 0 0 0 0 0 0 0 055.0629148.0214138.5482154.1536143.4321157.4598136.588499.863477.243358.434452.819555.0629QC'd by Selleck
Cytotoxic0.2093116.503485Complete curve; high efficacy-6.67921.3310.904546.5044163.0078-1.10 0 0 0 0 0 0 0 0 0 013.0869143.6239161.4686168.1578159.9801164.488797.670664.784668.491371.476350.62513.0869QC'd by Selleck
Cytotoxic0.295796.448284Complete curve; high efficacy-6.52921.82650.979336.1131132.5613-1.10 0 0 0 0 0 0 0 0 0 027.7595137.6757133.1247125.0579141.4133118.8792106.669652.975840.619540.756544.348527.7595QC'd by BIOMOL
Cytotoxic0.372296.5784Complete curve; high efficacy-6.42921.47870.980840.3311136.901-1.10 0 0 0 0 0 0 0 0 0 041.4841141.6948138.6029123.988145.2114122.9084114.816475.052646.365545.832838.682941.4841QC'd by BIOMOL
Cytotoxic0.013299.542284Complete curve; high efficacy-7.87920.50.859825.2368124.779-1.10 0 0 0 0 0 0 0 0 0 033.6254113.8403106.930467.885457.737956.717356.006446.273443.48929.15714.453233.6254QC'd by NCGCChem
Cytotoxic2.093175.060284Complete curve; high efficacy-5.67924.95490.948360.3489135.4091-1.10 0 0 0 0 0 0 0 0 0 060.7384119.1757138.3496139.0789136.1425149.2097137.4143127.2154116.932554.542266.866760.7384QC'd by ChemAxon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS-28PE-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inconclusive2.093152.377810Complete curve; partial efficacy; poor fit-5.67921.210.8868207.717155.33921.40 0 0 0 1 0 0 0 0 0 1147.1164.4833155.0085150.5868148.3401116.6514156.9711173.7174168.6881199.2135202.8962147.1QC'd by Microsource
Inconclusive0.005712.519610Complete curve; partial efficacy; poor fit-8.24044.95490.312131.5823119.06271.40 0 0 0 0 0 0 0 0 0 1127.1473120.0823122.1295115.8993137.6706122.1335127.163123.7971150.7316133.1825125.6113127.1473QC'd by SIGMA
Inconclusive0.00192110Complete curve; partial efficacy; poor fit-8.72921.10.8356134.2114113.21141.40 0 0 0 0 0 0 0 0 0 1119.1302117.2114127.4759130.4637129.9536131.9164134.6866133.4534131.6405137.8111137.2931119.1302QC'd by Pharmeks
Inconclusive0.066221.510Complete curve; partial efficacy; poor fit-7.17921.96730.9617136.1907114.69071.40 0 0 0 0 0 0 0 0 0 0137.9456114.6907115.3457114.9342114.9118125.4369132.2852136.9063134.4597139.5384132.1379137.9456QC'd by Sequoia
Inconclusive0.148221.099810Complete curve; partial efficacy; poor fit-6.82920.80.8442149.6919128.59211.40 0 0 0 0 0 0 0 0 0 0151.9116131.6919128.2754129.76129.967133.7039147.8377137.7359147.2819148.9579147.0679151.9116QC'd by Tocris
Inconclusive0.083330.510Complete curve; partial efficacy; poor fit-7.07920.30.9065152.817122.3171.40 0 0 0 0 0 0 0 0 0 0149.8479126.317131.9239133.2597133.1414138.2988138.8257144.3744142.6826141.1244150.4849149.8479QC'd by APAC
Inconclusive0.0032310Complete curve; partial efficacy; poor fit-8.52920.70.9042116.673193.67311.40 0 0 0 0 0 0 0 0 0 0115.023597.6731106.1567108.9656113.5207111.3295114.3155115.674116.5526117.8964119.9437115.0235QC'd by SigmaAldrich
Inconclusive0.001925.510Complete curve; partial efficacy-8.72921.55790.7725134.9997109.49971.20 0 0 0 0 0 0 0 0 0 0138.6831113.4997125.8748129.6566135.9028133.275139.8144131.171127.5454138.1274135.3784138.6831QC'd by SigmaAldrich
Inactive0-5.02920.80.4643103.7426121.954440 0 0 0 0 0 0 0 0 0 0106.6946111.4544125.2432128.5053127.1929113.4715124.3917121.815114.296116.6521111.8738106.6946QC'd by BIOMOL
Inactive04125.6815122.8795130.2888125.1136125.6652130.3074128.7078129.9384126.7494127.6785129.7132125.6815QC'd by BIOMOL
Inactive04136.2326163.4273142.6615146.3348166.6634150.6103158.3404165.0578162.7658150.3198139.9664136.2326QC'd by BIOMOL
Inactive0-7.37920.80.6066126.3684141.901940 0 0 0 0 0 0 0 0 0 0126.5818144.4019133.558143.8479137.0521128.3337135.1801122.2906134.5644123.4653125.8628126.5818QC'd by BIOMOL
Inactive0-4.92924.95490.7372120.4574134.013840 0 0 0 0 0 0 0 0 0 0120.7168134.5138134.0383138.0285138.2397129.2732130.6596135.9635130.2877134.4747123.0085120.7168QC'd by BIOMOL
Inactive0-6.87923.1320.4017111.9315106.526540 0 0 0 0 0 0 0 0 0 1105.5505105.9315109.5176101.4274110.4744106.5334110.4821115.977107.3312113.281111.1989105.5505QC'd by BIOMOL
Inactive0-4.67924.50450.6481132.5399143.83940 0 0 0 0 0 0 0 0 0 0132.7564143.839141.5609139.3268147.1235144.923140.6337146.4103146.2306145.3224141.4193132.7564QC'd by BIOMOL
Inactive0-4.57920.90.6882159.3525129.352540 0 0 0 0 0 0 0 0 0 0151.1525125.3525127.8444130.5681128.6677140.8596130.7582127.8002131.1106130.9549139.8805151.1525QC'd by BIOMOL
Inactive0-6.97920.40.9481115.525797.048340 0 0 0 0 0 0 0 0 0 0114.535699.525798.7112102.3247103.7206107.7162106.0966108.4061110.7209110.6769114.5412114.5356QC'd by BIOMOL
Inactive0-5.17922.40640.5201113.1718140.123540 0 0 0 0 0 0 0 0 0 0115.0077144.1235142.7954132.4372151.4407117.6804133.3272147.8257140.0962131.6466114.5804115.0077QC'd by BIOMOL
Inactive04129.9994131.8514126.6454132.768130.4791123.0823132.8921130.718134.7376125.1039126.4003129.9994QC'd by BIOMOL
Inactive0-5.97923.51170.87899.8725117.809540 0 0 0 0 0 0 0 0 0 0106.7355120.8095114.2948118.894116.6347119.8485116.4782116.0413102.243498.24195.0287106.7355QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-LP_1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010587.390386Complete curve; high efficacy-7.97921.55790.989332.5525119.9428-1.10 0 0 0 0 0 0 0 0 0 032.5973120.122108.670192.358749.68844.854932.131433.603134.763228.3332.048332.5973QC'd by Tocris
Cytotoxic0.008376.084786Complete curve; high efficacy-8.07922.40640.978834.0695110.1542-1.10 0 0 0 0 0 0 0 0 0 024.173108.041107.758381.913639.516542.556837.70132.500733.657937.059831.016624.173QC'd by Toronto Research
Cytotoxic0.018777.542886Complete curve; high efficacy-7.72921.78850.962734.3529111.8957-1.10 0 0 0 0 0 0 0 0 0 033.0008112.3533115.065889.919978.411730.490234.730734.354633.092838.520140.803433.0008QC'd by Selleck
Cytotoxic0.05988.700585Complete curve; high efficacy-7.22920.60.969436.3948125.0953-1.10 0 0 0 0 0 0 0 0 0 028.5989117.1885119.5312102.469690.645885.862360.636451.829952.266249.734541.128528.5989QC'd by Selleck
Cytotoxic0.033277.128185Complete curve; high efficacy-7.47920.70.965531.2029108.331-1.10 0 0 0 0 0 0 0 0 0 022.5571101.2018101.265588.845670.184569.842243.682140.23739.306637.25836.404722.5571QC'd by Selleck
Cytotoxic0.018779.858785Complete curve; high efficacy-7.72923.51170.958432.0611111.9199-1.10 0 0 0 0 0 0 0 0 0 013.2093112.4294107.1384115.125260.413141.924537.316331.47637.27735.928730.843213.2093QC'd by Cayman
Cytotoxic0.093586.449185Complete curve; high efficacy-7.02921.10.944937.248123.6972-1.10 0 0 0 0 0 0 0 0 0 026.2605129.9165117.2503108.9438120.53891.515551.119756.159151.860742.057332.899826.2605QC'd by Tocris
Cytotoxic0.020993.129385Complete curve; high efficacy-7.67921.46410.961833.1188126.2481-1.10 0 0 0 0 0 0 0 0 0 022.4794117.474125.7046121.844767.966156.055641.326142.215733.927132.351729.697222.4794QC'd by Selleck
Cytotoxic0.0332100.48585Complete curve; high efficacy-7.479210.970731.2298131.7149-1.10 0 0 0 0 0 0 0 0 0 025.5067135.567116.3384110.9262105.252653.915347.874942.057435.306632.7930.969525.5067QC'd by SIGMA
Cytotoxic0.029693.442184Complete curve; high efficacy-7.52923.92950.974823.6719117.114-1.10 0 0 0 0 0 0 0 0 0 025.7428100130.2442120.83397.558327.822521.54819.831323.18926.683424.643725.7428QC'd by SigmaAldrich
Cytotoxic0.372276.55184Complete curve; high efficacy-6.42921.210.930841.5458118.0968-1.10 0 0 0 0 0 0 0 0 0 026.8735126.0105102.8329112.503124.3981120.178987.830470.201454.107949.917250.88526.8735QC'd by ChemieTek
Cytotoxic0.132181.241484Complete curve; high efficacy-6.87924.95490.942234.404115.6454-1.10 0 0 0 0 0 0 0 0 0 026.3475111.8181103.4247109.6276115.8533135.698144.775439.68148.652328.651829.112426.3475QC'd by Microsource
Cytotoxic0.148282.701584Complete curve; high efficacy-6.82923.92950.980732.7831115.4845-1.10 0 0 0 0 0 0 0 0 0 029.9601112.1327117.5155121.9023104.2805119.069555.455342.556433.026630.915628.938629.9601QC'd by Selleck
Cytotoxic0.05976.700284Complete curve; high efficacy-7.22921.50950.976329.9655106.6658-1.10 0 0 0 0 0 0 0 0 0 021.9818106.9151109.4753101.075790.329271.880834.561430.807840.756634.092828.492121.9818QC'd by SantaCruz Bio
Cytotoxic0.020988.802383Complete curve; high efficacy-7.67923.51170.951216.2799105.0822-1.10 0 0 0 0 0 0 0 0 0 03.7081100.414107.4471102.660964.97134.98339.840114.997917.73926.496734.02243.7081QC'd by SIGMA
Cytotoxic0.041893.574583Complete curve; high efficacy-7.37922.18760.998417.8156111.39-1.10 0 0 0 0 0 0 0 0 0 017.4361109.284114.2073106.670495.671445.860321.91818.883416.506916.328316.984617.4361QC'd by ACC
Cytotoxic0.083378.232883Complete curve; high efficacy-7.07920.80.905521.999100.2318-1.10 0 0 0 0 0 0 0 0 0 02.109590.1163103.264689.018286.322667.714235.347539.808535.914336.921628.83652.1095QC'd by ChemAxon
Cytotoxic0.074390.137383Complete curve; high efficacy-7.12920.60.939423.0787113.2161-1.10 0 0 0 0 0 0 0 0 0 014.6398104.4157102.1008106.636185.983463.333350.656440.15953.402331.917625.558714.6398QC'd by Axon Medchem
Cytotoxic0.041884.768783Complete curve; high efficacy-7.37921.22210.965421.7645106.5332-1.10 0 0 0 0 0 0 0 0 0 018.8147105.573699.2727109.218868.570462.902925.88328.211225.408922.860621.049818.8147QC'd by Selleck
Cytotoxic0.0469101.067483Complete curve; high efficacy-7.32920.90.956722.9637124.0311-1.10 0 0 0 0 0 0 0 0 0 07.6524111.1073130.7357106.619390.519265.038238.879739.549834.132432.242524.93497.6524QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MOLP-8-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.2348112.884984Complete curve; high efficacy-6.62920.40.939237.0886149.9734-1.11 0 0 0 0 0 0 0 0 0 047.4866100.2991140.8419123.7999110.5725117.564587.825378.249885.531267.105248.08847.4866QC'd by SantaCruz Bio
Cytotoxic0.0332135.867784Complete curve; high efficacy-7.47920.40.868624.8504160.7181-1.10 0 0 0 0 0 0 0 0 0 09.5856132.6885149.7338116.748673.778973.989769.730568.018654.415855.950840.44799.5856QC'd by SIGMA
Cytotoxic2.0931100.118383Complete curve; high efficacy-5.67920.40.953450.966151.0844-1.10 0 0 0 0 0 0 0 0 0 067.4421149.8224143.8978144.1774136.6925121.0787121.338115.4935112.696598.792974.828167.4421QC'd by Tocris
Cytotoxic0.0132104.008283Complete curve; high efficacy-7.87921.92820.988715.4484119.4565-1.10 0 0 0 0 0 0 0 0 0 04.6572119.4565113.395898.070346.344719.738622.763617.901420.621915.88212.51264.6572QC'd by Selleck
Cytotoxic0.0235123.025483Complete curve; high efficacy-7.62920.40.833719.8641142.8896-1.10 0 0 0 0 0 0 0 0 0 012.2641131.0145115.543690.295153.905271.215162.338757.160461.969514.810235.382712.2641QC'd by Cayman
Cytotoxic0.209385.298783Complete curve; high efficacy-6.67920.70.933425.0186110.3173-1.10 0 0 0 0 0 0 0 0 0 027.0991109.8173117.737596.065379.189496.830975.536451.699233.826328.186136.413327.0991QC'd by NCGCChem
Cytotoxic3.317381.307483Complete curve; high efficacy-5.47922.33320.931557.6371138.9446-1.10 0 0 0 1 0 0 0 0 0 049.2543138.4338143.9848151.4142126.008995.5126125.5596148.3456124.31378.15369.765749.2543QC'd by Selleck
Cytotoxic0.005936.966482Complete curve; partial efficacy-8.22922.33320.9077119.6572156.6236-1.20 0 0 0 0 0 0 0 0 0 0121.5044156.5384152.389136.5428116.1001121.0618114.6459112.3913119.9242122.9008128.5083121.5044QC'd by Tocris
Cytotoxic0.0235114.209482Complete curve; high efficacy-7.62920.50.976314.7696128.979-1.10 0 0 0 0 0 0 0 0 0 010.4187119.189695.722479.624580.242657.691343.007536.236630.095223.109920.65110.4187QC'd by FLUKA
Cytotoxic3.722180.870382Complete curve; high efficacy-5.42924.95490.903234.983115.8532-1.10 0 0 0 0 0 0 0 0 0 031.7555109.588598.898113.8737107.8306136.1674134.0604103.0938120.4749.927837.402931.7555QC'd by Selleck
Cytotoxic0.093590.511982Complete curve; high efficacy-7.02922.40640.907611.9163102.4282-1.10 0 0 0 0 0 0 0 0 0 012.606679.81796.8282103.1563135.242367.22833.455113.67799.624510.775711.22312.6066QC'd by Selleck
Cytotoxic0.166394.761582Complete curve; high efficacy-6.77922.25260.98616.386111.1475-1.10 0 0 0 0 0 0 0 0 0 013.149108.3556124.8245103.3906106.2074102.246958.785121.215318.077319.677216.032513.149QC'd by Selleck
Cytotoxic0.5258104.154382Complete curve; high efficacy-6.279210.941418.3838122.5381-1.10 0 0 0 0 0 0 0 0 0 011.0314104.3828126.1461116.2417132.0669128.168183.354461.552952.656732.958721.753411.0314QC'd by JohnsHopkins
Cytotoxic0.1321103.787382Complete curve; high efficacy-6.87920.90.96614.4792118.2664-1.10 0 0 0 0 0 0 0 0 0 017.9536125.3305107.6763112.1488100.702673.069975.951528.288418.604519.064616.652717.9536QC'd by Axon Medchem
Cytotoxic0.0132114.512182Complete curve; high efficacy-7.87922.04790.990314.6838129.1959-1.10 0 0 0 0 0 0 0 0 0 013.3585136.7296116.4775107.708242.698923.621911.168115.726818.095413.321414.334613.3585QC'd by ChemieTek
Cytotoxic0.1321156.013482Complete curve; high efficacy-6.87920.40.9789-13.9595142.0539-1.10 0 0 0 0 0 0 0 0 0 02.982129.411119.3857103.9503100.891163.90856.490249.420432.44885.10223.55372.982QC'd by Selleck
Cytotoxic3.722184.036682Complete curve; high efficacy-5.42921.98870.889233.1062117.1428-1.10 0 0 0 0 0 0 0 0 0 022.583104.9664128.4651118.0164124.042993.0546124.0918125.7379103.197156.428452.504522.583QC'd by XcessBio
Cytotoxic1.320784.378182Complete curve; high efficacy-5.87924.44950.910828.6573113.0354-1.10 0 0 0 0 0 0 0 0 0 050.695598.1375111.271125.1555106.5195116.7283107.7109122.303149.824127.93655.97250.6955QC'd by Microsource
Cytotoxic0.525893.379882Complete curve; high efficacy-6.27922.33320.98319.1033112.4831-1.10 0 0 0 0 0 0 0 0 0 016.8591105.468124.7832114.5473109.601102.2654109.906561.363223.850621.146220.522416.8591QC'd by Selleck
Cytotoxic0.052698.055282Complete curve; high efficacy-7.27921.50950.986815.7184113.7736-1.10 0 0 0 0 0 0 0 0 0 012.9644114.8405118.277999.487995.383561.412321.163723.874615.920820.047211.588312.9644QC'd by Axon Medchem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM-M1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010576.742198Complete curve; high efficacy-7.97920.40.8143106.1488182.891-1.10 0 0 0 0 0 0 0 0 0 097.0213175.2098149.2496135.4049151.407123.166130.2765116.1855114.3842112.5027122.711897.0213QC'd by SigmaAldrich
Cytotoxic0.020959.606490Complete curve; high efficacy-7.67922.33320.874365.0446124.6509-1.10 0 0 0 0 0 0 0 0 0 042.5491114.2054125.0887133.638390.399669.076975.433362.892474.984266.982668.241342.5491QC'd by Selleck
Cytotoxic0.018799.387289Complete curve; high efficacy-7.72920.70.980954.5973153.9845-1.10 0 0 0 0 0 0 0 0 0 052144.7606143.678116.218996.581992.313370.116662.478959.112861.584152.567552QC'd by SynKinase
Cytotoxic0.417668.959788Complete curve; high efficacy-6.37923.51170.895189.8298158.7896-1.11 0 0 0 0 0 0 0 0 0 095.9522121.7497145.5234145.5172164.4127183.3401150.4309108.335677.511895.882489.823695.9522QC'd by Axon Medchem
Cytotoxic0.589969.181988Complete curve; high efficacy-6.22923.990.762995.3406164.5224-1.10 0 0 0 0 0 0 0 0 0 0109.573149.3937173.4718129.8513191.2497150.3213190.3378133.864783.187296.413691.5262109.573QC'd by Selleck
Cytotoxic0.0743107.054887Complete curve; high efficacy-7.12920.80.984554.8206161.8754-1.10 0 0 0 0 0 0 0 0 0 057.9387151.8563163.9611143.7973136.7288112.919683.16276.873368.177453.226952.637857.9387QC'd by Selleck
Cytotoxic0.148283.542787Complete curve; high efficacy-6.82924.44950.95860.4745144.0173-1.10 0 0 0 0 0 0 0 0 0 069.2734130.5346130.6652147.3751155.1668153.941881.695563.29659.260855.616355.513469.2734QC'd by Selleck
Cytotoxic1.177117.97687Complete curve; high efficacy-5.92920.30.8809103.6252221.6012-1.10 0 0 0 0 0 0 0 0 0 0124.3584204.1012213.7323210.6584195.2614187.4914165.4267159.6533180.5857156.7486132.0473124.3584QC'd by Microsource
Cytotoxic0.005986.11287Complete curve; high efficacy-8.22923.92950.940835.788121.9-1.10 0 0 0 0 0 0 0 0 0 016.9728119.2292123.80460.906149.612339.010736.652141.355244.341829.622331.979616.9728QC'd by Selleck
Cytotoxic0.661977.798687Complete curve; high efficacy-6.17921.46410.905587.7533165.5518-1.11 0 0 0 0 0 0 0 0 0 081.2811136.4201144.0668155.7612179.4399178.5787159.509126.3915103.3855100.192987.184981.2811QC'd by Selleck
Cytotoxic0.132189.890486Complete curve; high efficacy-6.87920.80.95149.0129138.9033-1.10 0 0 0 0 0 0 0 0 0 040.8231126.0203148.1813124.8099131.8805103.371579.016473.44667.02155.440553.384540.8231QC'd by Toronto Research
Cytotoxic0.4176102.258786Complete curve; high efficacy-6.37920.90.955864.4239166.6826-1.10 0 0 0 0 0 0 0 0 0 062.0508169.9186163.4857169.1241146.548155.8497143.523295.509585.826689.782263.021662.0508QC'd by JohnsHopkins
Cytotoxic1.481876.048286Complete curve; high efficacy-5.82921.64360.961186.8287162.8769-1.11 0 0 0 0 0 0 0 0 0 082.8262126.6031167.7674148.1546170.4052160.7596163.2256153.9322115.8888102.739187.384382.8262QC'd by Microsource
Cytotoxic0.93570.299185Complete curve; high efficacy-6.02921.10.944964.9721135.2712-1.10 0 0 0 0 0 0 0 0 0 054.1264136.8416133.7919124.0367139.8306136.3935126.542109.431383.56279.460279.257954.1264QC'd by Selleck
Cytotoxic0.1049113.233785Complete curve; high efficacy-6.97921.10.946739.4295152.6631-1.10 0 0 0 0 0 0 0 0 0 032.5405140.1803150.363153.1014157.369294.872271.375973.052248.593136.378239.149432.5405QC'd by Selleck
Cytotoxic0.0166145.913585Complete curve; high efficacy-7.77920.70.982429.6583175.5718-1.10 0 0 0 0 0 0 0 0 0 034.6378162.9357140.528136.147383.994477.337854.505136.927832.978933.61429.924334.6378QC'd by Selleck
Cytotoxic0.742787.807885Complete curve; high efficacy-6.12921.82650.8961.3799149.1877-1.10 0 0 0 0 0 0 0 0 0 043.6517125.4482151.4934151.5693138.7177162.0934165.3929104.484285.588670.237469.183243.6517QC'd by SynKinase
Cytotoxic0.002672.145785Complete curve; high efficacy-8.57921.22210.943724.741896.8875-1.10 0 0 0 0 0 0 0 0 0 016.212489.740360.566940.694133.868835.347627.530728.413321.997521.291722.494316.2124QC'd by Selleck
Cytotoxic0.935100.642185Complete curve; high efficacy-6.02920.70.92361.7833162.4254-1.10 0 0 0 0 0 0 0 0 0 057.3523168.1282144.1115151.7026171.4086158.4019133.5552112.5955103.328285.466988.368357.3523QC'd by Selleck
Cytotoxic2.635188.832385Complete curve; high efficacy-5.57920.80.900992.8317181.664-1.10 0 0 0 0 0 0 0 0 0 098.7032172.664175.775187.4451189.4966178.714170.8024149.3555161.8016111.5356120.77798.7032QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OCI_MY1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.093583.133787Complete curve; high efficacy-7.02920.60.973252.9139136.0477-1.10 0 0 0 0 0 0 0 0 0 054.7559135.1374118.648125.1116118.336796.366979.597475.149571.390359.692254.239654.7559QC'd by Selleck
Cytotoxic0.0332111.725186Complete curve; high efficacy-7.47920.30.926242.1257153.8508-1.10 0 0 0 0 0 0 0 0 0 051.7825144.6362112.8549103.828595.219288.923187.26580.966170.718165.599553.464751.7825QC'd by Cayman
Cytotoxic0.041882.751485Complete curve; high efficacy-7.37920.50.975933.8657116.617-1.10 0 0 0 0 0 0 0 0 0 028.5726108.62298.686993.798783.828667.416856.438356.969748.110946.342837.744328.5726QC'd by SynKinase
Cytotoxic0.029692.090785Complete curve; high efficacy-7.52920.50.938335.476127.5667-1.10 0 0 0 0 0 0 0 0 0 029.5556114.1336120.894588.726181.575576.202554.682455.648457.304545.91137.137429.5556QC'd by SynKinase
Cytotoxic0.186570.386984Complete curve; high efficacy-6.72922.72020.976138.0815108.4684-1.10 0 0 0 0 0 0 0 0 0 047.1917108.8739108.2531101.5408112.4163108.138570.335743.665234.539228.36141.664847.1917QC'd by JohnsHopkins
Cytotoxic0.417671.667384Complete curve; high efficacy-6.37922.40640.947943.4067115.074-1.10 0 0 0 0 0 0 0 0 0 033.3089105.574126.981118.3238117.612103.7019109.683463.443852.586453.630639.122233.3089QC'd by Selleck
Cytotoxic0.1049108.159184Complete curve; high efficacy-6.97920.30.95531.5875139.7466-1.10 0 0 0 0 0 0 0 0 0 043.3364131.0144114.5692101.756397.195681.028979.285179.03469.839955.06552.703143.3364QC'd by SynKinase
Cytotoxic0.0166112.88483Complete curve; high efficacy-7.77922.72020.988916.1533129.0373-1.10 0 0 0 0 0 0 0 0 0 013.2676116.3272134.3166126.014155.794523.838515.933916.952314.530314.265815.832113.2676QC'd by SIGMA
Cytotoxic0.468694.725883Complete curve; high efficacy-6.32920.60.955729.0284123.7542-1.10 0 0 0 0 0 0 0 0 0 035.6827133.5399103.9822117.9539112.0859105.55983.299274.084264.511341.029741.637235.6827QC'd by Selleck
Cytotoxic0.2635100.875583Complete curve; high efficacy-6.57920.90.896925.7615126.637-1.10 0 0 0 0 0 0 0 0 0 04.542104.9981131.3946122.3505135.6872112.0566.048557.839653.797641.533237.99754.542QC'd by ChemAxon
Cytotoxic0.0469103.265883Complete curve; high efficacy-7.32921.47870.994524.4756127.7413-1.10 0 0 0 0 0 0 0 0 0 022.0142133.8948120.7681119.4508105.615665.752534.739831.818124.476924.170924.920822.0142QC'd by Selleck
Cytotoxic0.468692.471283Complete curve; high efficacy-6.32922.33320.97228.9592121.4304-1.10 0 0 0 0 0 0 0 0 0 029.8907112.9759141.5986120.5517113.8929115.8225112.497662.870633.523828.959228.871129.8907QC'd by Selleck
Cytotoxic0.234889.204483Complete curve; high efficacy-6.62921.46410.977529.1453118.3497-1.10 0 0 0 0 0 0 0 0 0 030.577122.3185120.0124103.9641116.9025116.682575.578553.39729.776427.630331.59430.577QC'd by Selleck
Cytotoxic2.635188.363983Complete curve; high efficacy-5.579210.833353.4354141.7993-1.10 0 0 0 0 0 0 0 0 0 069.1826150.707126.8073140.1173122.6532128.5218127.1755136.3873123.344463.498261.630569.1826QC'd by Chemscene
Cytotoxic1.04994.696982Complete curve; high efficacy-5.97921.92820.986426.5166121.2135-1.10 0 0 0 0 0 0 0 0 0 022.4036111.8163115.5011118.7274126.8177125.7155124.411199.239253.489634.159726.65422.4036QC'd by BIOMOL
Cytotoxic0.132181.439182Complete curve; high efficacy-6.879210.970513.202594.6416-1.10 0 0 0 0 0 0 0 0 0 06.269984.6416100.214488.005489.829466.870145.105225.58927.265521.16810.12696.2699QC'd by Selleck
Cytotoxic0.083392.852382Complete curve; high efficacy-7.07920.40.970612.2421105.0944-1.10 0 0 0 0 0 0 0 0 0 015.231897.301484.070587.11564.466159.841648.860238.500140.277931.426921.966115.2318QC'd by Selleck
Cytotoxic0.023580.806982Complete curve; high efficacy-7.62920.60.988914.690995.4978-1.10 0 0 0 0 0 0 0 0 0 011.797688.131284.02266.582754.926541.216133.27229.074823.708316.203515.847511.7976QC'd by Tocris
Cytotoxic0.001259.123982Complete curve; partial efficacy-8.92924.95490.858799.4449158.5687-1.20 0 0 0 0 0 0 0 0 0 0103.2631152.614894.492295.000194.342694.4109100.4664111.3588107.5709103.868592.1541103.2631QC'd by Selleck
Cytotoxic0.417694.690582Complete curve; high efficacy-6.37922.18760.986124.3029118.9934-1.10 0 0 0 0 0 0 0 0 0 021.4583113.0531121.9635115.8336128.0296109.3466109.274655.291834.103826.512620.023521.4583QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_NCIH929-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.148296.190585Complete curve; high efficacy-6.82923.92950.992444.5048140.6953-1.10 0 0 0 0 0 0 0 0 0 037.5464136.9515141.9942144.5132137.0086139.274769.470850.205143.474741.413450.930437.5464QC'd by JohnsHopkins
Cytotoxic0.012983.536684Complete curve; high efficacy-7.89041.47870.997823.8147107.3513-1.10 0 0 0 0 0 0 0 0 0 023.9151110.1823102.343496.995170.752740.620228.6625.881524.655321.871925.213523.9151QC'd by Chemscene
Cytotoxic0.023592.464784Complete curve; high efficacy-7.62921.96730.956723.2254115.6902-1.10 0 0 0 0 0 0 0 0 0 04.0573111.7434116.8232109.391975.447232.990933.705930.026330.264932.170612.76854.0573QC'd by ChemieTek
Cytotoxic0.288175.880584Complete curve; high efficacy-6.54041.82650.968341.6685117.5491-1.10 0 0 0 0 0 0 0 0 0 036.3204119.5479107.4971113.5971126.3084112.3175118.484679.974545.966145.122348.307136.3204QC'd by Selleck
Cytotoxic0.295781.009684Complete curve; high efficacy-6.52923.19250.926140.4734121.483-1.10 0 0 0 0 0 0 0 0 0 011.322115.4342118.2478121.3497132.2979117.0883107.092749.913546.654851.648750.637411.322QC'd by Prestwick Chemical; Inc.
Cytotoxic0.2635116.509584Complete curve; high efficacy-6.57920.60.970641.249157.7585-1.10 0 0 0 0 0 0 0 0 0 040.8193148.2389152.8144145.5181150.8832117.900795.735582.368280.769561.721251.108540.8193QC'd by Toronto Research
Cytotoxic0.052688.20883Complete curve; high efficacy-7.27921.28760.994223.4223111.6302-1.10 0 0 0 0 0 0 0 0 0 017.5003110.0308111.5061103.845494.601259.384438.839430.849224.832526.413122.221717.5003QC'd by LC Labs
Cytotoxic0.052675.902483Complete curve; high efficacy-7.27922.04790.973721.174997.0774-1.10 0 0 0 0 0 0 0 0 0 018.3476101.803486.025499.482590.080350.384429.228830.857823.374816.245614.543118.3476QC'd by Tocris
Cytotoxic0.052679.925683Complete curve; high efficacy-7.27921.37230.966323.9977103.9232-1.10 0 0 0 0 0 0 0 0 0 017.613998.4232100.1087114.286377.500461.650832.015431.605425.732323.840827.908417.6139QC'd by SynKinase
Cytotoxic0.020990.480783Complete curve; high efficacy-7.67920.90.977517.1515107.6322-1.10 0 0 0 0 0 0 0 0 0 06.471996.9766103.361585.574958.317441.067631.175422.007623.02321.414419.28116.4719QC'd by Selleck
Cytotoxic0.005393.642383Complete curve; high efficacy-8.279210.969714.5291108.1714-1.10 0 0 0 0 0 0 0 0 0 08.149699.284981.998249.133631.068631.287422.589621.209613.435211.247510.25858.1496QC'd by SynKinase
Cytotoxic0.014894.690583Complete curve; high efficacy-7.82921.17050.98217.423112.1135-1.10 0 0 0 0 0 0 0 0 0 012.0947103.9614109.053682.852955.000727.887130.356624.600918.123514.68813.793112.0947QC'd by SynKinase
Cytotoxic0.093596.642483Complete curve; high efficacy-7.02921.66040.992224.5734121.2158-1.10 0 0 0 0 0 0 0 0 0 025.6091121.7166119.6038122.5533110.023190.71841.660937.931622.388222.677922.400325.6091QC'd by Selleck
Cytotoxic0.046982.967883Complete curve; high efficacy-7.32924.95490.917922.6763105.644-1.10 0 0 0 0 0 0 0 0 0 02.6388101.9106107.1814103.9277109.288434.581138.965938.548133.351423.30352.61952.6388QC'd by NCI
Cytotoxic0.0296105.787183Complete curve; high efficacy-7.52920.50.883422.0136127.8007-1.10 0 0 0 0 0 0 0 0 0 04.7056117.0952117.3948102.779158.640855.617851.251852.864946.062539.792825.44594.7056QC'd by Selleck
Cytotoxic0.0209126.334483Complete curve; high efficacy-7.67920.80.98917.1119143.4463-1.10 0 0 0 0 0 0 0 0 0 016.0678134.7593122.167111.586876.247354.666237.345223.48931.102310.658718.953916.0678QC'd by Tocris
Cytotoxic0.0074100.270383Complete curve; high efficacy-8.12922.04790.993616.8213117.0916-1.10 0 0 0 0 0 0 0 0 0 023.4575117.6101105.197473.040125.850513.91814.847215.041116.016216.504218.359623.4575QC'd by Selleck
Cytotoxic0.0235108.888982Complete curve; high efficacy-7.62920.70.99411.7255120.6144-1.10 0 0 0 0 0 0 0 0 0 013.4791114.531297.322186.143674.13546.996429.785423.38115.47313.144913.473313.4791QC'd by BIOMOL
Cytotoxic0.0235110.59682Complete curve; high efficacy-7.62921.62660.976412.0566122.6526-1.10 0 0 0 0 0 0 0 0 0 012.2889128.4612120.246294.57586.24920.741516.111913.685812.951413.59113.568112.2889QC'd by FLUKA
Cytotoxic0.041884.248182Complete curve; high efficacy-7.37920.80.942513.632697.8807-1.10 0 0 0 0 0 0 0 0 0 06.907782.5934102.65586.90856441.11432.79328.119227.818519.73737.48046.9077QC'd by Otava
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HepG2
External ID: CHEMBL5303715
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL395
ChEMBL Target Name: HepG2
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: EU-OPENSCREEN
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
2.8IC50 relative=2800nMActive
8.5IC50 relative=8500nMActive
8.2IC50 relative=8200nMActive
8.7IC50 relative=8700nMActive
15IC50 relative=15000nMInactive
1.1IC50 relative=1100nMActive
8.3IC50 relative=8300nMActive
7.8IC50 relative=7800nMActive
5.3IC50 relative=5300nMActive
4.5IC50 relative=4500nMActive
2.5IC50 relative=2500nMActive
12.5IC50 relative=12500nMInactive
1IC50 relative=1000nMActive
0.7IC50 relative=700nMActive
3.6IC50 relative=3600nMActive
2.7IC50 relative=2700nMActive
13.1IC50 relative=13100nMActive
1.9IC50 relative=1900nMActive
11.8IC50 relative=11800nMInactive
50IC50 relative=50000nMInactive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Nuclear receptor subfamily 4 group A member 2
External ID: CHEMBL5392230
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2023
Volume: 66
Issue: 22
First Page: 15362
Last Page: 15369
DOI: 10.1021/acs.jmedchem.3c01467

Target ChEMBL ID: CHEMBL5002
ChEMBL Target Name: Nuclear receptor subfamily 4 group A member 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Delta Tm=-3.5degrees C
Delta Tm=-0.94degrees C
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cytochrome P450 2D6
External ID: CHEMBL4479074
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2016
Volume: 26
Issue: 16
First Page: 4003
Last Page: 4006
DOI: 10.1016/j.bmcl.2016.06.088

Target ChEMBL ID: CHEMBL289
ChEMBL Target Name: Cytochrome P450 2D6
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
FC=0.9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: BPDCN-GEN22
Protocol: A total of 500 exponentially growing Gen2.2 cells were seeded per well in 5 uL of media (RPMI + Glutamine, without phenol red plus10% FBS and 1X Pen/Strep) into 1536-well solid white high base tissue culture treated Greiner One Bio Plates (789173-F), using a multidrop combi dispenser and a small sterile cassette. Compounds and controls totaling 23nL per well (negative control DMSO and positive control 9.2 uM Bortezomib-final) were immediately added to the plates using a 1536 head pin tool from Kalypsys. The plates were then covered with stainless steel gasket lids from Kalypsys and incubated for 48 hours at 37C under 95% relative humidity with 5% CO2. After 48 hours, the plates were removed and allowed to reach room temperature before 3 uL of Cell Titer Glo reagent (Promega) were added using an Aurora Flying Reagent Dispenser Bioraptor. The plates were then spun at 1000 rpms to remove bubbles and incubated for 15 minutes at room temperature before reading on a ViewLux using a luminescent filter with a 10 second exposure. The relative luciferase units were used to calculated percent activity using DMSO as 100% and Bortezomib as 0%.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Activator9.349537.11450Partial curve; high efficacy; poor fit-5.02924.50450.3394139.866102.75152.30 0 0 0 0 0 0 1 0 0 188.0524128.0096112.723388.625579.246188.4591116.5125107.434240.612105.1422136.374988.0524QC'd by BIOMOL
Activator05142.8394114.1417111.508167.841110.3078162.3881116.8787143.5866138.3617142.280496.0848142.8394QC'd by BIOMOL
Activator0.0066105.25930Complete curve; high efficacy; poor fit-8.17920.70.8893112.3492217.60861.30 0 1 0 0 0 0 0 0 0 1149.7744206.0416175.796299.9709145.4635125.3281120.2334135.1946115.4803122.261890.372149.7744QC'd by BIOMOL
Activator0529.4231126.395381.16586.1405110.3352124.4199134.8609111.812889.3843231.3882107.438329.4231QC'd by BIOMOL
Activator05143.615387.7329109.6233117.133130.2435108.007371.945131.4159458.2894127.4181102.4514143.6153QC'd by BIOMOL
Activator20.931115.76070Partial curve; high efficacy; poor fit-4.67924.50450.672852.682168.44282.30 0 0 0 0 0 0 0 1 0 057.3383156.9875210.0745196.4426169.3007145.4793168.5143122.6219177.1228240.8839147.192657.3383QC'd by BIOMOL
Inactive0-4.87923.51170.74543.7363121.376141 0 0 0 0 0 0 0 0 0 04.995969.848372.4018110.8591122.5541161.1408130.7083144.5237100.537122.353447.45634.9959QC'd by BIOMOL
Activator11.7704120.38030Partial curve; high efficacy; poor fit-4.92924.95490.6857256.5786136.19822.30 0 0 0 0 0 0 0 0 0 1129.6573124.8033153.6337147.2807166.633130.3024101.8421144.7083155.0295116.7688231.6699129.6573QC'd by BIOMOL
Activator05123.0403128.8699210.7699190.2566146.8479215.4495109.2714124.0291164.0907204.8081137.4596123.0403QC'd by BIOMOL
Activator3.722132.65680Complete curve; high efficacy; poor fit-5.42924.95490.427689.2254121.88221.30 1 0 0 0 0 0 0 0 0 0100.467287.1822158.1858123.8552104.2031121.5711143.849137.3495134.381992.833779.7182100.4672QC'd by BIOMOL
Activator1.4818129.40820Complete curve; high efficacy; poor fit-5.82920.90.7836.537165.94521.30 0 1 0 0 0 0 0 0 0 042.5687179.6537123.5264118.8734141.6283179.6193162.418995.5446129.667848.147154.875542.5687QC'd by BIOMOL
Activator0.066223.89990Complete curve; high efficacy; poor fit-7.17924.95490.3972157.0608133.16091.30 0 0 0 1 0 0 0 0 0 0156.4182131.6383146.4008133.9209120.0163196.9193161.7274189.7061147.8016155.1127132.5334156.4182QC'd by BIOMOL
Activator1.662639.6820Complete curve; high efficacy; poor fit-5.77924.95490.639368.8456108.52751.30 0 0 0 0 0 0 0 1 0 058.2968104.901585.3011114.5667123.321105.330499.8094125.775785.4017139.460580.25458.2968QC'd by BIOMOL
Activator7.4266132.89130Complete curve; high efficacy; poor fit-5.12921.96730.519645.9316178.8231.30 0 0 0 0 0 1 0 0 0 046.3684155.3315110.8327150.523132.3744223.2312259.9272370.7888225.3172120.431280.827846.3684QC'd by BIOMOL
Activator26.350664.97420Partial curve; high efficacy; poor fit-4.57924.50450.778765.5932130.56752.30 0 0 0 0 0 0 1 0 0 070.9665137.7579130.009140.9582142.8709108.0684128.1229122.723883.1025134.1418125.198170.9665QC'd by BIOMOL
Activator0.066242.96070Complete curve; high efficacy; poor fit-7.17924.95490.3774171.918128.95731.30 0 0 0 1 0 0 0 0 0 0186.2327131.3763114.3898169.2145100.0259417.4076185.7832137.3011196.8317196.7498128.9228186.2327QC'd by BIOMOL
Activator20.931357.07590Partial curve; high efficacy-4.67921.62660.9443496.1622139.08632.10 0 0 0 0 0 0 0 0 0 0450.0879120.9857123.3915150.1624127.9468154.6912129.5912127.2593186.5804191.2598245.2113450.0879QC'd by BIOMOL
Inactive0-5.52923.19250.683822.4254105.728640 0 0 0 0 1 0 0 0 0 026.507899.36974.653492.2028101.995999.5674165.511173.039787.234839.914614.050826.5078QC'd by BIOMOL
Activator4.685957.81330Complete curve; high efficacy; poor fit-5.32924.95490.7192154.795696.98231.30 0 0 1 0 0 0 0 0 0 0156.374697.7645116.034697.6905140.541797.0357110.7006102.992857.4166132.01153.4092156.3746QC'd by BIOMOL
Activator23.48541.33940Partial curve; high efficacy; poor fit-4.629210.526488.6415129.98092.30 1 0 0 0 0 0 0 0 0 097.9229133.620896.1141131.6403139.2531128.2736113.9247123.5101139.3218112.8157122.812997.9229QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: BPDCN-CAL1
Protocol: A total of 500 exponentially growing Cal-1 cells were seeded per well in 5 uL of media (RPMI + Glutamine, without phenol red plus10% FBS and 1X Pen/Strep) into 1536-well solid white high base tissue culture treated Greiner One Bio Plates (789173-F), using a multidrop combi dispenser and a small sterile cassette. Compounds and controls totaling 23nL per well (negative control DMSO and positive control 9.2 uM Bortezomib-final) were immediately added to the plates using a 1536 head pin tool from Kalypsys. The plates were then covered with stainless steel gasket lids from Kalypsys and incubated for 48 hours at 37C under 95% relative humidity with 5% CO2. After 48 hours, the plates were removed and allowed to reach room temperature before 3 uL of Cell Titer Glo reagent (Promega) were added using an Aurora Flying Reagent Dispenser Bioraptor. The plates were then spun at 1000 rpms to remove bubbles and incubated for 15 minutes at room temperature before reading on a ViewLux using a luminescent filter with a 10 second exposure. The relative luciferase units were used to calculated percent activity using DMSO as 100% and Bortezomib as 0%.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Activator0596.9812124.7788111.862799.1911109.8132115.8543122.7029124.978711.9636106.6618115.3296.9812QC'd by BIOMOL
Activator5.899218.55230Partial curve; high efficacy; poor fit-5.22921.59360.403698.2719116.82422.30 0 0 0 0 0 0 0 0 0 1112.1416116.3242116.0395124.1925105.021117.4347113.456126.6776109.8792109.999101.2806112.1416QC'd by BIOMOL
Activator0.0053140Complete curve; high efficacy; poor fit-8.27921.010.4672116.3066102.30661.30 0 0 0 0 0 0 0 0 0 0115.6225103.8066106.9288110.734112.8603113.7842118.7801117.453127.3511110.7768108.9356115.6225QC'd by BIOMOL
Inactive0-4.77922.72020.92567.4047112.261140 0 0 0 0 0 0 0 0 0 011.761291.0017111.0572112.5676117.0089126.6768110.9798121.4511106.8272107.246267.780211.7612QC'd by BIOMOL
Activator05113.2428112.6901103.509103.9003102.6066116.1617101.937105.552969.0952107.2108101.4004113.2428QC'd by BIOMOL
Inactive0-4.77923.1320.95268.0992113.058640 0 0 0 0 0 0 0 0 0 03.8949109.004119.742107.3798101.7335102.3462118.5813117.9993118.1915117.629571.87863.8949QC'd by BIOMOL
Inactive0-4.87921.75290.9755-3.302111.272940 0 0 0 0 0 0 0 0 0 09.2164111.826113.9215114.6486108.2664119.8515109.8219108.562295.88998.580743.56689.2164QC'd by BIOMOL
Activator16.626124.87630Partial curve; high efficacy; poor fit-4.77921.69240.347492.6528117.5292.30 0 0 0 0 0 0 0 0 0 095.2635108.3173105.9493113.7331109.0795117.0458137.3809129.6073122.6355108.5839108.131495.2635QC'd by BIOMOL
Activator05112.755117.1575116.8914112.2579112.3712121.4293115.3043115.3089107.1441121.4021110.4386112.755QC'd by BIOMOL
Inactive0-4.77922.18760.988510.0687113.747640 0 0 0 0 0 0 0 0 0 017.4423109.6122112.2788114.0082120.8283115.6809111.1114117.7232111.2532104.416766.142317.4423QC'd by BIOMOL
Inactive0-5.52924.50450.98317.5135117.599740 0 0 0 0 0 0 0 0 0 012.8583129.2377109.7349118.9217115.1912116.2997113.6696110.2515109.547223.646124.047512.8583QC'd by BIOMOL
Activator18.654846.19170Partial curve; high efficacy; poor fit-4.72924.50450.824765.8443112.03612.30 0 0 0 0 0 0 0 0 0 066.877599.5341112.8886111.9402121.8966115.7352104.7994116.4969106.3102117.563697.729766.8775QC'd by BIOMOL
Activator23.48562.95570Partial curve; high efficacy; poor fit-4.62924.0950.872243.341106.29672.30 0 0 0 0 0 0 0 0 0 048.3003107.43119.6331100.973899.0434113.2845112.3172103.148797.5313103.168398.057948.3003QC'd by BIOMOL
Inactive0-6.17920.90.991413.9467122.275740 0 0 0 0 0 0 0 0 0 016.0493121.1837125.2456121.294112.6383110.2161103.73666.18643.993533.762219.090416.0493QC'd by BIOMOL
Inactive0-4.72922.72020.979810.0162112.861540 0 0 0 0 0 0 0 0 0 012.0535113.9203107.621117.2056105.2005113.2177112.1472115.6483117.9416106.765277.54812.0535QC'd by BIOMOL
Activator10.490433.93550Complete curve; high efficacy; poor fit-4.97924.95490.813387.1253121.06091.30 0 0 0 0 0 0 0 0 0 087.3266113.333118.7195122.2141120.0529128.8421109.7936131.8841120.4381122.173491.04487.3266QC'd by BIOMOL
Activator05106.0617105.1595.4872110.3326113.665116.9489116.2338108.1254105.7991103.2361100.4977106.0617QC'd by BIOMOL
Inactive0-5.97921.10.982913.892796.744840 0 0 0 0 0 0 0 0 0 017.662101.545396.414590.127794.5053100.607678.9371.978945.24927.207613.540717.662QC'd by BIOMOL
Activator0.74275.43280Complete curve; high efficacy; poor fit-6.12924.95490.4642117.2092111.77641.30 0 0 0 0 0 0 0 0 0 1111.9075115.2092111.9615115.9844108.9243109.7763107.7652113.0327118.4395118.7792114.168111.9075QC'd by BIOMOL
Activator05109.5103113.4756109.9484115.0474114.0506116.6804107.3915105.6838121.9588114.747114.6431109.5103QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B1
External ID: CHEMBL2077920
Protocol: N/A
Comment: Journal: J. Biol. Chem.
Year: 1999
Volume: 274
Issue: 1
First Page: 37161
Last Page: 37168
DOI: 10.1074/jbc.274.52.37161

Target ChEMBL ID: CHEMBL1697668
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeActivity Comment
Activityinhibitor [+]
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B1
External ID: CHEMBL2077919
Protocol: N/A
Comment: Journal: J. Biol. Chem.
Year: 1999
Volume: 274
Issue: 1
First Page: 37161
Last Page: 37168
DOI: 10.1074/jbc.274.52.37161

Target ChEMBL ID: CHEMBL1697668
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeActivity Comment
Activityinhibitor [+]
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Rhizomucor pusillus
External ID: CHEMBL5333264
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2023
Volume: 246
First Page: 115010
Last Page: 115010
DOI: 10.1016/j.ejmech.2022.115010

Target ChEMBL ID: CHEMBL5291663
ChEMBL Target Name: Rhizomucor pusillus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=1ug.mL-1
MIC90=3.6ug.mL-1
MIC90=11ug.mL-1
MIC90=11ug.mL-1
MIC90=11ug.mL-1
MIC90=1.2ug.mL-1
MIC=0.4ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Liver
External ID: CHEMBL4011674
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Hepatology
Year: 2014
Volume: 60
Issue: 3
First Page: 1015
Last Page: 1022
DOI: 10.1002/hep.27206

Target ChEMBL ID: CHEMBL613642
ChEMBL Target Name: Liver
ChEMBL Target Type: TISSUE - Target is a healthy or diseased tissue
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
IC50Non-Toxic
IC50Non-Toxic
IC50Non-Toxic
0.01424IC50=14.24nM
IC50Non-Toxic
0.1IC50>100nM
0.1IC50>100nM
0.0494IC50=49.4nM
IC50Non-Toxic
IC50Non-Toxic
IC50Non-Toxic
0.1IC50>100nM
IC50Non-Toxic
0.0662IC50=66.2nM
IC50Non-Toxic
0.03197IC50=31.97nM
IC50Non-Toxic
IC50Non-Toxic
0.1IC50>100nM
0.1IC50>100nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:3-hydroxy-3-methylglutaryl-coenzyme A reductase
External ID: CHEMBL832902
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2005
Volume: 15
Issue: 4
First Page: 1027
Last Page: 1032
DOI: 10.1016/j.bmcl.2004.12.042

Target ChEMBL ID: CHEMBL402
ChEMBL Target Name: HMG-CoA reductase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.01IC50=10nM
0.006IC50=6nM
0.00789IC50=7.89nM
0.00725IC50=7.25nM
0.0087IC50=8.7nM
0.009IC50=9nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Bile salt export pump
External ID: CHEMBL4011672
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Hepatology
Year: 2014
Volume: 60
Issue: 3
First Page: 1015
Last Page: 1022
DOI: 10.1002/hep.27206

Target ChEMBL ID: CHEMBL6020
ChEMBL Target Name: Bile salt export pump
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
41.7IC50=41700nM
28.2IC50=28200nM
2.2IC50=2200nM
10.9IC50=10900nM
25.1IC50=25100nM
16.2IC50=16200nM
24.7IC50=24700nM
27.4IC50=27400nM
12.9IC50=12900nM
8IC50=8000nM
7.9IC50=7900nM
3.75IC50=3750nM
3.4IC50=3400nM
13IC50=13000nM
36.1IC50=36100nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3292030
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 13
First Page: 2924
Last Page: 2927
DOI: 10.1016/j.bmcl.2014.04.078
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Homo sapiens
External ID: CHEMBL4011678
Protocol: N/A
Comment: Journal: Hepatology
Year: 2014
Volume: 60
Issue: 3
First Page: 1015
Last Page: 1022
DOI: 10.1002/hep.27206

Target ChEMBL ID: CHEMBL372
ChEMBL Target Name: Homo sapiens
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNon-Toxic
ActivityToxic
ActivityToxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityToxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityToxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityToxic
ActivityNon-Toxic
ActivityToxic
ActivityNon-Toxic
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Homo sapiens
External ID: CHEMBL4011675
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Hepatology
Year: 2014
Volume: 60
Issue: 3
First Page: 1015
Last Page: 1022
DOI: 10.1002/hep.27206

Target ChEMBL ID: CHEMBL372
ChEMBL Target Name: Homo sapiens
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
0.0053Cmax=5.3nM
18.1Cmax=18100nM
0.005Cmax=5nM
0.21Cmax=210nM
0.025Cmax=25nM
0.193Cmax=193nM
0.087Cmax=87nM
2.87Cmax=2870nM
4.18Cmax=4180nM
3.36Cmax=3360nM
15.15Cmax=15150nM
2.946Cmax=2946nM
0.086Cmax=86nM
1.211Cmax=1211nM
5.06Cmax=5060nM
6.8Cmax=6800nM
0.65Cmax=650nM
12.139Cmax=12139nM
7.993Cmax=7993nM
26.939Cmax=26939nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR163
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00043.0633-0.75412.1391.5904-0.3839-1.1415-0.39720.3007-0.97562.17540.8962-0.70775.67143.0633QC'd by ACCInactive0-4.475110.3403
Inactive0-4.47512.58840.5668.5-0.350840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.86480.1037-0.8896-0.4598-1.86570.62930.11860.461.3225-4.0423-0.7584-0.26931.61755.8648QC'd by ACCInactive0-4.87510.96410.6959
Inconclusive26.603243.928410Partial curve; high efficacy-4.57511.75290.950842-1.92842.10 0 0 0 0 0 0 0 0 0 0 0 0 0 032.0411-4.94030.1803-1.7907-1.04840.7187-2.0655-1.6464-0.9268-3.163-1.69577.805612.275332.0411QC'd by ACCInconclusive14.960143.862810Partial curve; partial efficacy-4.82511.96730.9669
Inactive0-4.77511.17050.46487-2.090540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8087-2.6379-0.128-0.3535-5.64580.03570.6444-4.5926-6.7421-1.9435-0.94861.98431.17355.8087QC'd by ACCInactive0-9.12514.95490.3263
Inactive00041.42561.18570.65356.04820.39286.34775.07265.4272.92610.04150.34843.0231-0.03451.4256QC'd by RTIInactive0
Inactive0004-1.88582.35057.09190.33143.3965-1.34684.203-0.8178-0.3747-1.06299.6715-2.4181-0.776-1.8858QC'd by RTIInactive0
Inactive0410.19018.95610.325512.63911.810913.69999.62495.66968.687812.306313.512815.91738.562510.1901QC'd by RTIInactive0
Inactive0004-0.41364.053-1.44611.85171.21114.06523.09290.81280.93140.5931-2.12422.4304-0.681-0.4136QC'd by RTIInactive0
Inactive00040.842-0.47542.86752.25690.4215-1.5297-2.07673.62060.9619-1.5025.02941.288-1.44990.842QC'd by RTIInactive0
Inconclusive0.00215.510Complete curve; partial efficacy; poor fit-8.70534.50450.795614-1.51.40 0 0 0 0 0 0 0 0 0 0 1 1 0 1-9.16440.693913.915611.436716.139211.324915.416415.994911.157614.795712.415311.295913.1797-9.1644QC'd by RTIInactive0-4.10534.95490.806
Inactive0004-6.75480.2459-1.60532.34130.73913.9972-1.3651-1.7233-3.4099-1.711.5906-2.29334.2594-6.7548QC'd by RTICytotoxic74.351433.63620Partial curve; partial efficacy; poor fit-4.12874.0450.7048
Cytotoxic40.421673.990940Partial curve; high efficacy-4.39342.25260.9604-70.17013.8208-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.09312.03564.92412.49064.22714.26826.20750.1594-0.95685.63330.0103-1.2879-37.614-61.0931QC'd by RTICytotoxic50.887883.280741Partial curve; high efficacy-4.29342.40640.9709
Cytotoxic69.171880.051341Partial curve; high efficacy-4.16014.50450.9543-74.39445.6568-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.67343.72427.29138.5895.08398.48319.02366.00472.81232.47474.97363.2009-4.4556-62.6734QC'd by RTICytotoxic69.171870.875120Single point of activity-4.16014.95490.9592
Inactive00045.1373.18785.21485.1644.96454.2219-0.33642.43436.57815.74133.06254.20694.86615.137QC'd by RTIInactive0
Cytotoxic78.824137.545620Single point of activity-4.10334.95490.8973-36.54561-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.20472.52230.11410.250.7493-2.2911-0.3071-0.86864.6455-1.007-1.8243.89684.0876-29.2047QC'd by RTICytotoxic78.824134.719820Partial curve; partial efficacy; poor fit-4.10334.95490.8207
Cytotoxic54.894739.278640Partial curve; high efficacy-4.26053.1320.9761-38.27861-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.1488-1.31041.12321.8921-0.72281.240.11850.53022.330.65950.21212.9868-14.3497-33.1488QC'd by RTICytotoxic54.894761.362221Partial curve; partial efficacy-4.26052.18760.9745
Inactive00043.14233.21915.8769-1.7146-0.4681-0.26044.11687.43091.98552.08331.94551.2669-1.29783.1423QC'd by RTIInactive0
Inactive0004-2.77945.33392.168-2.2813-0.6736-2.0788-16.89162.24013.5698-1.00744.02973.9198-1.0474-2.7794QC'd by RTIInactive0-4.79590.40.487
Inactive0004-0.88360.18994.02715.7421-2.1210.15651.51726.95692.32841.27492.76063.93542.593-0.8836QC'd by RTIInactive0
Inactive0-6.964110.3333-0.776340 0 0 0 0 0 0 0 0 0 0 0 0 0 13.24412.13982.31925.45162.7289-2.13923.47190.2244-0.6655-1.88570.9391.8723-2.31343.2441QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cytochrome P450 2C9
External ID: CHEMBL4479131
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2016
Volume: 26
Issue: 16
First Page: 4003
Last Page: 4006
DOI: 10.1016/j.bmcl.2016.06.088

Target ChEMBL ID: CHEMBL3397
ChEMBL Target Name: Cytochrome P450 2C9
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
FC=2.3
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:firefly luciferase
External ID: LUC790
Protocol: Tox21 Assay Protocol Summary:

3 ul of substrate mix (containing 50 mM Tris acetate, pH 7.6, 13.3 mM Mg acetate, 10uM D-luciferin, 10uM ATP, 0.01% Tween, 0.05% BSA and dH2O ) is dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS.) 1 uL of firefly luciferase mix (containing 50 mM Tris acetate, pH 7.6, 0.04 uM P. pyralis luciferase, 0.01% Tween, 0.05% BSA and dH2O) was then delivered by FRD to each well. Luciferase activity was then measured using a ViewLux CCD imager.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000074871 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000679832 uM-Replicate_1Activity at 0.0001616562 uM-Replicate_1Activity at 0.0003744726 uM-Replicate_1Activity at 0.0007728037 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00651 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.2010.90.8471131.115440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.54731.4227-0.0927-0.73721.51692.33370.74961.98550.53323.45031.33282.53683.90686.069.5473QC'd by LightBiologicalsActivator70.63415.92510Partial curve; partial efficacy; poor fit-4.1510.90.7402
Inactive00043.83132.48656.35684.00543.84138.25791.63143.11833.93691.19885.93977.44213.27273.8313QC'd by LightBiologicalsInactive0
Inhibitor27.540425.239720Partial curve; partial efficacy-4.563.06540.9464-24.23971-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.86643.54850.58071.273.5792-1.0506-0.74551.82640.64041.29330.55871.0439-10.0294-21.8664QC'd by LightBiologicalsInactive0-4.364.50450.8982
Inhibitor70.574761.494341Partial curve; high efficacy-4.15142.30310.9936-61.34170.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.84970.69220.24130.03541.62351.4902-0.6178-0.2576-0.1338-0.7741-1.5037-5.7105-17.9277-46.8497QC'd by LightBiologicalsInhibitor62.899858.392741Partial curve; high efficacy-4.20143.1320.9871
Inactive0-4.39890.90.710380.988440 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7160.31890.18581.95122.60040.67990.14231.73831.70660.79292.27513.9265.04871.716QC'd by LightBiologicalsInactive0
Inactive0004-1.2464-0.1277-3.31990.07610.0272-0.171-0.9426-1.275-0.8314-1.0122-0.1704-0.7926-0.2083-1.2464QC'd by LightBiologicalsInactive0
Inactive00049.0594-4.22375.94818.69258.92016.96137.5769-4.56141.7618.73328.6084-3.34-3.90129.0594QC'd by LightBiologicalsInactive0
Inactive00041.81981.5048-2.86521.29632.0381-3.75161.90181.93420.96122.92531.90792.69043.8991.8198QC'd by LightBiologicalsInactive0-4.19893.92950.4592
Inactive00041.0427-2.9040.2976-1.36752.4811.58460.60181.9111.8233-2.31412.7932-0.1252-3.80621.0427QC'd by LightBiologicalsInactive0
Inactive00041.81572.32444.23827.73370.21471.78012.640.32671.7625.77573.74973.61055.36231.8157QC'd by LightBiologicalsInactive0-4.51490.50.3892
Inhibitor89.358431.923510Single point of activity-4.04894.95490.9445-30.92351-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.10290.8105-1.44111.7887-0.1850.69522.96312.16590.03891.2506-0.78660.32282.6099-24.1029QC'd by LightBiologicalsInhibitor89.358427.433610Single point of activity-4.04894.95490.9335
Inactive0-6.39480.90.42680.05953.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.61711.84673.25183.75243.33334.00713.8712-0.9505-1.43963.0690.48362.44510.1858-1.6171QC'd by LightBiologicalsInactive0
Inactive00040.0907-0.4901-3.2387-0.7092-0.3212-0.94770.426-0.2568-0.3555-0.5594-0.8083-0.44290.5340.0907QC'd by LightBiologicalsInactive0
Inactive00040.8222.29930.05141.4340.8292-3.84692.04270.53252.7743.15713.841.89041.86440.822QC'd by LightBiologicalsInactive0
Inhibitor79.640758.055341Partial curve; high efficacy-4.09893.62720.9858-58.8675-0.8123-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8693-1.39271.2532-1.8476-3.00891.0377-0.085-0.0864-1.0068-0.2868-1.8043-4.6859-9.7906-46.8693QC'd by LightBiologicalsInhibitor70.979924.628520Partial curve; partial efficacy-4.14893.57220.9379
Inactive0-4.04894.50450.8551-8.6034140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.33621.44610.98591.11170.77190.52781.33360.63411.98470.66550.3564-1.19960.4705-6.3362QC'd by LightBiologicalsInactive0-4.24891.46410.7616
Inhibitor31.705522.975520Partial curve; partial efficacy-4.49892.09370.9159-21.97551-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.22960.1079-1.25660.0804-0.4464-0.9265-0.24241.22035.1564-0.16970.1335-8.2794-14.2156-21.2296QC'd by SIGMAInhibitor39.914927.035120Partial curve; partial efficacy-4.39891.47870.9029
Inactive00041.68681.80593.04642.90412.6745-1.14845.3851.35853.20093.01323.66774.258211.12191.6868QC'd by SIGMAInactive0
Inactive0004-0.01532.91587.60184.7593.8923-5.03062.21774.13765.41963.00133.93875.23166.3628-0.0153QC'd by SIGMAInhibitor89.358418.599210Partial curve; partial efficacy; poor fit-4.04894.95490.8509
Inactive00043.7853-0.6681.31811.1372-0.42441.41111.52592.25831.1924-5.84795.2943-0.63157.19593.7853QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR541
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO, was added using a Flying Reagent Dispenser to generate a final concentration of 50 nM CITCO inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inhibitor3.349141.215910Single point of activity-5.47514.95490.5085-42.7363-1.5203-30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-8.087121.89-8.6781-3.6855-6.25695.4433-2.2253-6.5947-10.7583-4.5705-16.1608-16.3686-5.5938-8.0871QC'd by ACCInactive0
Inhibitor2.660331.350422Complete curve; partial efficacy-5.57514.95490.7593-35.7832-4.4328-1.20 0 0 0 0 0 0 0 0 0 0 0 0 1 1-7.07487.0287-3.7117-8.93987.0191-8.6003-10.5811-9.6323-3.5772-9.7824-21.4714-32.0269-13.6825-7.0748QC'd by ACCInactive0
Inhibitor29.8493180.333140Partial curve; high efficacy-4.52511.86170.9403-183.9808-3.6476-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-139.3794-6.9891-4.5485-2.48725.72942.1105-4.4422-5.01950.98326.5263-18.8291-30.3545-53.8001-139.3794QC'd by ACCInhibitor29.8493162.790140Partial curve; high efficacy-4.52513.24750.9553
Inactive0-4.77512.40640.4777-19.93010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.4418-5.3665-6.0776-0.6378-0.7746-5.95928.056814.4063-4.2029-2.83313.6942-1.1786-14.0414-17.4418QC'd by ACCInactive0-4.57513.1320.6731
Inactive0-4.04014.95490.487724-5.718340 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6907-9.6058-16.8485-11.179-0.45450.0756-9.022-7.6078-4.898-2.6992-0.66814.3314-11.422917.6907QC'd by RTIActivator64.553243.03530Partial curve; partial efficacy-4.19013.92950.9117
Inactive0004-19.84863.3433-23.4364-34.1329-6.2414-5.0556-25.546-8.9103-6.9329-28.1976-6.81633.8592-42.036-19.8486QC'd by RTIActivator67.057937.01130Partial curve; partial efficacy; poor fit-4.17353.67720.7941
Inactive0-4.02734.95490.655322-3.294740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.0345-2.80161.8842-7.0081-1.7985-7.3345-5.4629-6.0156-0.7765-1.4972-8.9956-1.9725-7.487516.0345QC'd by RTIInactive0-4.27732.33320.6095
Inactive00047.8644-12.2433-5.1181-4.04961.28844.3493-4.5231-6.8637-4.8147-7.4445-2.1022-11.7632-20.07367.8644QC'd by RTIInactive0-4.37991.96730.5769
Inactive000412.77776.2553-5.7998-3.9544-6.27073.8508-4.3153-0.2911-4.79463.74813.8044.64191.374312.7777QC'd by RTIInactive0-4.28464.95490.3638
Inactive0-4.20534.44950.6434-17.42521.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.7713.79853.86442.4904-4.2833.78225.42352.6092-2.38-3.39182.70615.627-2.5037-15.771QC'd by RTIInactive0-5.20534.95490.321
Inhibitor5.9059106.654984Complete curve; high efficacy-5.228710.9844-102.49964.1553-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.8049.49943.6503-0.42471.07452.82466.38180.0721-15.1461-24.7454-55.3584-79.6141-94.3827-85.804QC'd by RTIInhibitor4.691398.416784Complete curve; high efficacy-5.32870.90.9674
Inactive0-4.69341.55790.702223-4.449740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3595-2.1806-3.3591-6.2651-0.28090.121-6.0475-11.7066-7.89250.86856.2708-0.375526.069416.3595QC'd by RTIActivator71.880946.06290Single point of activity-4.14344.95490.7673
Inhibitor69.1718135.093943Partial curve; high efficacy-4.16013.06540.9789-149.2252-14.1313-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-117.8714-2.1311-17.2291-13.9078-13.6919-19.6465-13.3695-15.7919-17.4807-14.0473-10.7354-16.145-44.1916-117.8714QC'd by RTIInhibitor54.9451147.633342Partial curve; high efficacy-4.26012.40640.9628
Inactive0-6.14174.95490.4637-11.0778-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.73651.2389-2.2448-12.4683-0.62132.0757-1.40511.6174-8.0337-11.8106-11.9614-1.3448-17.9815-2.7365QC'd by RTIInactive0-4.34170.50.4602
Inhibitor8.844263.970182Complete curve; high efficacy-5.05331.46410.9355-69.4155-5.4454-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.4281-3.3461-7.3817-5.25411.5957-7.1494-6.1151-2.5632-12.7008-17.0044-40.829-49.2957-77.8583-59.4281QC'd by RTIInhibitor7.882431.683321Complete curve; partial efficacy-5.10332.33320.905
Inhibitor19.477457.938541Partial curve; partial efficacy-4.71051.34430.9334-57.56260.376-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.0338-12.41210.71942.24359.20663.0773-1.07773.1429-3.055-5.8935-11.5387-32.2284-42.404-52.0338QC'd by RTIInhibitor77.540938.538210Single point of activity-4.11054.95490.5991
Inactive0004-3.3574-9.0659-5.0523-7.9611.8345-6.6475-6.4054-4.0807-7.994-5.2589-4.8636-18.8381-16.5327-3.3574QC'd by RTIInactive0-5.70264.95490.3553
Inactive0-4.09594.95490.659231.5-0.506240 0 0 0 0 0 0 0 0 0 0 0 0 0 025.14185.9174-1.2243-9.58850.3121-2.79136.44825.5515-1.4762-0.4167-3.92814.3971-4.45225.1418QC'd by RTIActivator56.764849.34910Partial curve; partial efficacy-4.24591.80790.7545
Inactive000411.60064.5643-3.7194-10.097311.42282.41525.31161.6689-4.6133-3.7747-3.13611.8656-13.87311.6006QC'd by RTIInactive0-4.14513.29750.4562
Inactive0-4.06414.95490.569122-3.35640 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3590.1187-1.3367-4.6228-5.1472-1.2162-0.1657-0.04880.0689-5.7723-5.23-1.7902-11.963316.359QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR611
Protocol: Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195, was added using a Flying Reagent Dispenser to generate a final concentration of 0.75 uM PK11195 inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.36620.69570.44051.11090.5787-0.2699-0.32331.18450.0326-1.0092-1.73120.8267-2.1104-2.3662QC'd by SigmaAldrichInactive0
Inactive0004-0.2849-0.47850.10371.13040.3494-1.2942-2.3851-1.60740.1233-0.8459-1.8941-2.6451-0.2138-0.2849QC'd by SigmaAldrichInactive0
Activator53.984430.302520Partial curve; partial efficacy-4.26772.04370.980730-0.30252.20 0 0 0 0 0 0 0 0 0 0 0 0 0 022.9705-0.53970.19140.0778-0.1425-0.2776-1.9188-0.46281.1362-0.8514-0.42823.186710.348822.9705QC'd by SigmaAldrichActivator27.056334.152540Partial curve; high efficacy-4.56771.47810.9607
Inactive0-7.768610.69720.758810.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.08229.0278.56537.5724.21540.90080.24680.02675.66910.0433-7.0E-4-2.28440.3557-1.0822QC'd by SIGMAInactive0
Activator17.351737.620340Partial curve; high efficacy-4.76073.06540.989337.3935-0.22682.10 0 0 0 0 0 0 0 0 0 0 0 0 0 124.0027-1.13920.1686-0.1252-1.4390.2351-0.49480.65421.28420.05961.310721.815534.209324.0027QC'd by SIGMAActivator4.890445.728181Complete curve; high efficacy-5.31070.70.9547
Inactive00040.5220.023-1.1865-1.4762-0.05160.6407-0.0477-0.5943-1.0553-3.4872-1.7526-1.5011-0.45170.522QC'd by SIGMAInactive0-5.56914.95490.4552
Inactive0-4.27133.29750.65377-0.991840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.71270.1065-2.9589-3.3265-0.1367-0.53720.1194-0.7792-2.1668-3.2131-0.01280.58790.97235.7127QC'd by SigmaAldrichInactive0-4.12134.95490.6439
Inactive0004-4.945-2.5611-5.5604-5.5744-3.7841-2.51970.8205-4.2283-4.7634-6.5963-6.2633-3.1896-5.8718-4.945QC'd by SIGMAInactive0
Inactive0-4.16290.60.42327-1.160340 0 0 0 0 0 0 0 0 0 0 0 0 0 04.3597-0.362-3.0077-3.05030.2438-1.01930.3335-0.4699-1.28130.401-0.46414.3554-0.91184.3597QC'd by SIGMAInactive0-5.51292.33320.8433
Inactive0004-0.70380.0361-3.7089-1.7915-1.25830.16870.69770.1566-2.4696-3.4971-1.51-1.5395-3.4697-0.7038QC'd by SIGMAInactive0
Inactive0004-1.2777-1.6943-2.5955-3.5033-1.64891.17161.2363-2.1104-2.9787-3.3438-1.1157-1.1422-1.1735-1.2777QC'd by SIGMAInactive0
Inactive0004-0.56630.288-2.3707-2.7283-0.63382.07513.38390.0802-2.4707-3.83610.0879-0.2454-2.8389-0.5663QC'd by SIGMAInactive0-4.85851.88510.9504
Inactive0004-1.1005-0.9792-1.7954-2.6037-0.12-0.26040.3413-0.8959-1.9784-3.2297-1.6711-0.0062-3.6975-1.1005QC'd by SIGMAInactive0
Inactive0004-1.2459-4.784-9.0537-2.2125-3.0446-0.91621.9784-0.3992-6.2878-10.5833-9.5972-2.1042-10.227-1.2459QC'd by SIGMAInactive0
Inactive0004-1.0084-1.7104-1.9369-2.0369-1.6802-0.573-0.47480.085-2.3375-4.3727-2.4796-2.5942-2.7424-1.0084QC'd by SIGMAInactive0
Inactive0004-0.9643-2.3604-0.8724-2.1936-0.583-0.2670.1582-0.3325-2.7466-3.9462-1.2392-0.1393-2.9256-0.9643QC'd by SigmaAldrichInactive0
Inactive0004-6.2696-3.3484-4.8795-5.0177-4.9214-3.95680.8092-3.9748-5.0443-6.7588-5.093-3.1627-6.7773-6.2696QC'd by ChemServiceInactive0
Inactive0004-3.7787-1.21870.3496-1.1618-0.178-0.02990.1049-1.7277-1.4204-3.3075-1.8639-0.2976-4.4158-3.7787QC'd by SIGMAInactive0
Inactive0004-5.5543-3.7243-4.3348-6.0183-4.46860.85250.2555-1.1073-5.5639-6.2665-7.6529-4.829-7.4675-5.5543QC'd by SIGMAInactive0
Activator21.579778.216381Complete curve; high efficacy-4.6662.47290.975179.1210.90471.10 0 0 0 0 0 0 0 0 0 0 0 0 0 079.9059-0.6357-0.03330.1670.65420.84030.39860.65146.9793-1.6191.148938.519460.089479.9059QC'd by FisherActivator24.212873.718240Partial curve; high efficacy-4.6161.10.9797
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR224
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195 (final concentration = 0.75 uM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.7001-2.07971.16113.0882-0.077102.1698.77392.9614-2.21710.116619.58354.13960.7001QC'd by ACCInactive0-4.52511.10.5248
Inactive00046.4354-1.02440.0097-0.0933-1.85581.1884-0.92732.35142.15013.76020.1771-1.03550.10946.4354QC'd by ACCInactive0
Inconclusive14.960164.783610Partial curve; high efficacy-4.82511.55790.966665.88741.10382.10 0 0 0 0 0 0 0 0 0 0 0 0 0 064.59921.6564-1.48951.3624-0.33672.53023.07761.2257-1.3673-1.46236.837225.336734.910764.5992QC'd by ACCInconclusive29.849380.826810Partial curve; high efficacy-4.52512.25260.8962
Inactive00047.00811.6498-1.43860.50060.40820.79470.89650.34840.35820.30331.35526.99592.91727.0081QC'd by ACCInactive0
Inactive00043.05635.54866.72620.53512.71380.70682.23040.2851-1.53215.16263.86991.54890.8433.0563QC'd by RTIInactive0
Inactive00040.74666.36313.94348.84614.56211.575.48974.19182.16295.86320.50451.34453.99310.7466QC'd by RTIInactive0
Inactive00040.67381.12332.28591.01811.5966-0.43621.77940.2945-1.37111.71640.89490.65662.50770.6738QC'd by RTIInactive0
Inactive00041.00343.59883.74021.61832.4828-24.1996-11.8417-15.26063.54570.8131-0.0321-11.9734-1.31061.0034QC'd by RTIInactive0
Inactive0-4.18464.95490.9125-10.752.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.31021.06850.91324.13362.67391.81972.26761.87431.57794.70882.78081.3363-11.4583-9.3102QC'd by RTIInactive0-3.83464.50450.8486
Inactive0-4.15534.95490.6213-8.5472540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7063.03746.28947.39888.83679.30074.16635.48521.16012.64973.10975.62653.3473-6.706QC'd by RTIInactive0-4.50531.13410.921
Inactive0-4.07872.90230.7611-27.65215.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.71016.68477.71693.3955.081315.63232.80533.07480.28617.9345.15692.3389-1.44-19.7101QC'd by RTICytotoxic74.351457.123720Single point of activity-4.12872.90230.9124
Cytotoxic57.09755.000921Partial curve; partial efficacy-4.24343.57220.9446-54.11980.881-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.68171.44960.64610.87374.0413-0.6397-8.70514.50811.25313.61011.83811.5671-14.0711-46.6817QC'd by RTICytotoxic57.09772.527141Partial curve; partial efficacy-4.24342.35310.9803
Cytotoxic69.1718108.736442Partial curve; high efficacy-4.16012.63840.9717-107.06951.6669-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.11334.12134.26247.21762.32561.1447-8.56171.58873.20240.90921.8827-6.6983-25.0645-81.1133QC'd by RTICytotoxic54.9451118.001241Partial curve; high efficacy-4.26012.12110.9982
Inactive00041.23831.33150.88153.39274.07264.82921.16914.05412.98531.32630.32392.28032.47551.2383QC'd by RTIInactive0
Cytotoxic62.612238.428920Partial curve; partial efficacy; poor fit-4.20332.53340.9423-35.92892.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.44074.56793.2733.0004-0.82787.03151.32971.03340.94391.5864-0.53831.1816-10.0481-27.4407QC'd by RTICytotoxic55.803256.613421Partial curve; partial efficacy-4.25332.53340.9455
Cytotoxic34.636240.085420Partial curve; partial efficacy-4.46052.78680.9485-35.58544.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-37.55547.86573.08136.25493.50321.57814.64299.84995.08361.63343.0637-4.2032-21.4975-37.5554QC'd by RTICytotoxic48.92563.310741Partial curve; partial efficacy-4.31052.40640.966
Inactive0-4.95263.51170.4728-12.1793140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.88662.10451.60872.2705-1.9686-0.7779-1.63741.02741.49992.1762.5-23.0661-2.7817-0.8866QC'd by RTIInactive0-4.15262.63840.6052
Inactive0004-2.84033.5493.05938.34540.08545.4167-0.89290.03223.37180.29422.8684-1.08252.444-2.8403QC'd by RTIInactive0-4.09594.95490.8672
Inactive00040.57120.96791.09642.61560.08615.51343.14970.57852.83021.933.1832-1.67453.16860.5712QC'd by RTIInactive0
Inactive0-4.51414.95490.6339-9.2283240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.63681.3480.78612.61030.0177-0.69933.3843-0.57490.00933.38765.62053.6707-9.3569-0.6368QC'd by RTICytotoxic68.537737.040120Partial curve; partial efficacy; poor fit-4.16412.90230.9194
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR404
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO (final concentration = 50 nM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-1.2885-8.2133-8.16350-7.1502-6.0582-1.0685-6.9497-7.74221.4318-0.484-9.89-5.9739-1.2885QC'd by LightBiologicalsInactive0
Inactive0-4.21374.50450.3794-2.0019-11.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.2267-13.6359-11.5589-12.427-11.9862-12.3014-2.0849-11.776-12.2205-11.2807-10.5655-12.6043-10.0799-3.2267QC'd by SIGMAInactive0
Inactive0004-18.8355-16.5392-15.7843-14.6365-14.6435-14.8247-15.1826-17.2997-17.0567-15.571-15.4498-16.8771-18.7769-18.8355QC'd by SIGMAInactive0
Cytotoxic61.130668.499141Partial curve; partial efficacy-4.21373.57220.9855-82.6763-14.1772-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.8305-13.3313-15.7246-16.9851-15.1291-16.6431-12.0943-15.0603-13.2228-10.6311-12.392-15.5076-28.0786-69.8305QC'd by SIGMACytotoxic61.130688.918141Partial curve; high efficacy-4.21372.47290.9648
Inactive0004-9.4937-8.4802-2.4154-6.8019-7.6968-8.7013-4.9931-5.9136-8.161-5.4834-5.5854-7.8666-8.6242-9.4937QC'd by LightBiologicalsInactive0-8.06374.95490.5744
Inactive0-4.21373.29750.784-19.65540.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.54620.30110.54811.68972.3515-1.76286.6762-2.18030.3036-2.6294-0.6711-0.2348-3.468-15.5462QC'd by SIGMAInactive0-4.21370.40.6227
Inactive0004-0.8117-4.0669-9.8967-11.0574-6.4365-5.9282-6.3535-7.6972-5.2867-9.8338-1.3993-0.8947-7.6295-0.8117QC'd by SIGMAInactive0
Cytotoxic61.503855.678321Partial curve; partial efficacy-4.21113.990.9569-57.7149-2.0366-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-48.64770.26981.6175-2.9758-3.96481.7183-4.47090.3089-5.9715-1.9196-1.5152-1.5012-11.187-48.6477QC'd by ChemServiceInactive0-4.21114.95490.8972
Inactive0-4.11374.95490.6896-23.3009040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.75070.5104-1.55631.8378-3.19332.5092-0.693-8.08051.92620.04853.9244-2.18611.6782-17.7507QC'd by SIGMAInactive0-4.21374.0950.6638
Cytotoxic60.5715107.680742Partial curve; high efficacy-4.21771.86170.9797-127.4822-19.8016-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.5775-19.6657-16.6526-20.809-21.6607-19.7704-14.2217-18.8965-22.5975-21.7271-20.6249-34.5795-53.8367-96.5775QC'd by EPACytotoxic42.8813102.238741Partial curve; high efficacy-4.36771.96730.9874
Cytotoxic34.201550.561640Partial curve; partial efficacy-4.4661.46410.9284-54.0991-3.5375-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.0918-2.7848-1.0730.0864-3.1155-8.38860.2833-5.2666-5.937-8.2702-10.3681-18.193-25.3466-50.0918QC'd by CrescentCytotoxic30.482144.89120Partial curve; partial efficacy-4.5161.47810.9399
Inactive0-3.96370.80.6909-31.6-3.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23-4.3769-2.78840.141-3.552-4.8242-6.7976-4.9877-2.8309-6.1986-3.8792-6.6066-8.0591-23QC'd by Sigma DiscoveryCPRCytotoxic61.130637.500120Single point of activity-4.21373.62720.9475
Inactive00042.7896-2.2890.3967-3.4023-0.5931-3.73261.98680.266-0.04370.42130.10770.45910.0122.7896QC'd by SIGMAInactive0
Inactive00040.26690.57262.32333.2007-0.42921.18692.47032.29592.39542.45931.99820.27692.75730.2669QC'd by SIGMAInactive0
Inactive00040.15290.81242.78170.7373.17970.4171.1829-3.29880.4225-0.650.0220.90230.99470.1529QC'd by SIGMAInactive0
Inactive0-4.11374.95490.7475-10.5412240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11761.66523.16792.25360.69250.89822.26921.6541.01862.7189-0.12983.29222.2598-7.1176QC'd by SIGMAInactive0-4.56374.50450.3801
Inactive0004-3.2742-0.57391.18390.6992-0.1356-0.9956-3.9472-0.31020.02640.46931.55660.2082-3.8232-3.2742QC'd by SIGMAInactive0
Inactive0004-0.7927-6.5931-0.004-0.87430.5458-3.7497-2.0427-2.5866-3.6954-3.9867-18.7143-2.0222.5912-0.7927QC'd by SIGMAInactive0
Inactive0004-13.9982-8.8449-6.7122-3.2554-8.551-4.4661-2.4558-5.8647-10.1231-5.4289-3.8809-5.1227-8.4815-13.9982QC'd by SIGMAInactive0
Inactive0004-0.2549-3.2147-2.0568-1.3426-0.21941.32071.5504-1.1495-1.6104-0.5283-1.0103-2.0348-1.3745-0.2549QC'd by LightBiologicalsInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC875
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.3468-0.10070.0358-0.33470.23222.509-4.5860.2540.48071.16460.75384.1574-4.8525-0.3468QC'd by SIGMAInactive0
Inactive0004-3.3197-5.6995-7.8071-6.0662-4.9082-8.0484-7.708-4.8984-5.8365-2.5967-1.1821-5.7986-3.0963-3.3197QC'd by SigmaAldrichInactive0
Inactive00041.84520.97091.1435-0.24060.0731-0.12051.2062-0.18330.0921.20720.47061.31020.49521.8452QC'd by SIGMAInactive0-4.01730.70.5777
Inhibitor34.131725.96160Partial curve; partial efficacy-4.46682.33320.9617-25.96160-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.9681.69630.1516-1.09160.4925-0.73560.52772.66582.0E-4-2.8872-3.0257-4.5147-15.6179-24.968QC'd by SIGMAInhibitor48.212321.71050Partial curve; partial efficacy-4.31681.82650.8711
Inactive00041.39531.94521.30180.9104-0.31670.42261.07071.9713-0.37872.93970.83462.12710.21931.3953QC'd by SigmaAldrichInactive0
Inactive0-4.06334.95490.4301-7.0921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.24341.0247-0.6334-0.0593-0.5529-0.870.3563-3.05990.0772-2.04451.2375-0.9179-0.0839-4.2434QC'd by SIGMAInactive0-4.31333.51170.5308
Inactive0-5.75854.95490.3744-2.0452140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.39762.44991.9442.7333-0.72910.18521.02430.39980.1524-5.0377-4.45790.10940.3382-0.3976QC'd by SigmaAldrichInactive0
Inactive00044.02841.30910.502-2.96730.6114-3.0343-5.43691.67780.79992.43120.8290.0491.04384.0284QC'd by Alfa AesarInactive0
Inactive0-5.26464.95490.4346-2.0801140 0 0 0 0 0 0 0 0 0 0 0 0 0 11.98340.29922.4906-0.22330.3752.7141.88570.4384-0.23811.8609-3.01220.5146-3.40011.9834QC'd by SIGMAInactive0
Inactive00042.63350.03471.26840.123-0.3218-0.7076-0.30731.1541.4491.46540.89010.0407-0.34962.6335QC'd by SIGMAInactive0
Inactive0-4.09724.95490.45685-0.300340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4899-1.55050.48970.6246-0.8749-0.70910.3983-0.38271.38450.1489-2.3336-0.5514-0.29293.4899QC'd by SigmaAldrichInactive0
Activator42.573923.761320Partial curve; partial efficacy-4.37091.46410.9148240.23872.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.55410.00531.42-0.16480.3750.50141.6438-0.125-0.76833.78914.61832.97299.933520.5541QC'd by SIGMAActivator60.13733020Partial curve; partial efficacy-4.22092.53340.9705
Inactive00042.55290.4063-0.01020.18952.3191-1.84951.7387-1.9418-1.54353.99270.02911.34360.7672.5529QC'd by SIGMAInactive0-8.36331.28760.3456
Inactive00041.41240.5842.30430.55631.00343.2421-0.03291.7832-2.03062.37860.03731.3846-0.48531.4124QC'd by ChemServiceInactive0
Inactive00043.2372-0.06260.30520.0902-0.17460.25520.3996-0.2881.25733.132-0.27620.86140.24633.2372QC'd by SIGMAInactive0
Inactive00042.54410.50790.20260.3539-0.13770.985-0.3504-1.23841.32581.2338-2.15810.15631.45512.5441QC'd by SIGMAInactive0
Inactive0-4.17223.67720.6648-5.8375140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.03120.75431.06750.67620.09292.30830.48760.50432.7882-0.24950.6636-0.05580.1164-4.0312QC'd by City ChemicalInactive0
Inhibitor17.334135.94590Complete curve; high efficacy-4.76113.1320.981-35.94590-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.7947-1.1822-0.3985-2.19492.5399-2.8881-1.15330.37421.44382.4728-1.8207-20.2287-32.2128-36.7947QC'd by InterchemInhibitor15.44939.10510Complete curve; high efficacy-4.81112.33320.9633
Inactive0-4.17994.0950.4925-4.84510.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.62090.76960.04541.12750.09010.13020.2945-0.00821.2284-0.19962.4956-2.29050.011-3.6209QC'd by SIGMAInhibitor46.785537.00050Partial curve; partial efficacy-4.32991.69240.9362
Inactive0004-3.6855-2.20722.44460.09531.2718-2.0196-1.5529-1.1351-0.9412-2.5691-0.9983-2.4138-2.9275-3.6855QC'd by SIGMAActivator5.431631.161281Complete curve; high efficacy-5.26511.34430.9707
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: TSHR942
Protocol: Tox21 Assay Protocol Summary:

TSHR-Hek293 cells were dispensed at 800 cells/4uL/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool, followed by 1 ul medium containing Ro20-1724. The plates were incubated at room temperature for 30 min. 2.5 ul/well of cAMP-d2 and 2.5ul/well of anti-cAMP-cryptate was added respectively into the assay plates using a Flying Reagent Dispenser. After 1 hr incubation at room temperature, the fluorescence intensity in the plates was measured using an Envision plate reader. Each test compound was measured at 15 concentrations and in triplicates.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W615-Activity_Score-Replicate_1W615-Curve_Description-Replicate_1W615-Fit_LogAC50-Replicate_1W615-Fit_HillSlope-Replicate_1W615-Fit_R2-Replicate_1W615-Fit_InfiniteActivity-Replicate_1W615-Fit_ZeroActivity-Replicate_1W615-Fit_CurveClass-Replicate_1W615-Excluded_Points-Replicate_1W615-Max_Response-Replicate_1W615-Activity at 0.0000060039 uM-Replicate_1W615-Activity at 0.0000137707 uM-Replicate_1W615-Activity at 0.0000545120 uM-Replicate_1W615-Activity at 0.0001296300 uM-Replicate_1W615-Activity at 0.0003002588 uM-Replicate_1W615-Activity at 0.0006197232 uM-Replicate_1W615-Activity at 0.00170 uM-Replicate_1W615-Activity at 0.00522 uM-Replicate_1W615-Activity at 0.013 uM-Replicate_1W615-Activity at 0.030 uM-Replicate_1W615-Activity at 0.068 uM-Replicate_1W615-Activity at 0.153 uM-Replicate_1W615-Activity at 0.349 uM-Replicate_1W615-Activity at 1.067 uM-Replicate_1W615-Activity at 3.267 uM-Replicate_1W615-Activity at 8.386 uM-Replicate_1W615-Activity at 18.95 uM-Replicate_1W615-Activity at 42.46 uM-Replicate_1W615-Activity at 92.41 uM-Replicate_1W615-Activity at 240.3 uM-Replicate_1W615-Activity at 872.4 uM-Replicate_1W615-Activity at 1849.0 uM-Replicate_1W615-Activity at 4135.0 uM-Replicate_1W615-Activity at 9246.0 uM-Replicate_1W615-Activity at 20670.0 uM-Replicate_1W615-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100046.71165.91411.01090.48573.26231.84362.00641.99435.44978.12683.9593.84525.64976.711610004-2.748
Inactive100041.15973.45360.9481-0.52418.4135-5.3381-0.2037-1.12098.426911.44892.56851.52615.51131.159710004-0.2798
Inactive1000413.619319.24979.80112.092519.851720.559717.738615.489515.20168.327325.730421.994613.226513.619310004-8.0616
Inactive10004-0.01774.084512.92615.3982.40380.8257.68639.482714.70655.1151-0.75927.9425-1.263-0.017710004-2.1171
Inactive100043.1252.35685.09388.475210.98810.10777.68738.07633.86263.49345.21091.85468.95053.12510004-15.6867
Inactive100047.46870.77720.070411.33447.3155.46854.97583.73919.3253-1.65574.71633.480410.62097.468710-8.61680.30.3731-11.65381840 0 0 0 0 0 0 0 0 0 0 0 0 0 12.1384
Inactive10-5.36373.51170.3912-2-8.811940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.9865-8.0324-8.6353-2.0989-6.6589-13.3952-12.0664-9.0355-11.3374-6.2204-1.73390.0195-5.6888-2.986510004-24.5166
Activator37.79197.19310004-6.7723-1.27140.9157-4.0255-10.6032-5.96680.5902-3.4901-1.7017-13.963-2.6223-0.0117-2.2437-6.77230Partial curve; high efficacy-4.42261.22210.920696.8641-0.32892.10 0 0 0 0 0 0 0 0 0 0 0 0 0 081.1085
Inactive100041.5703-3.83490.9073-2.0903-1.2647-1.4311-3.4337-4.0019-0.4467-1.59621.99851.4791-3.3903-4.9221.570310004-4.9352
Inconclusive10004-0.6217-8.1939-9.7496-1.3131-1.96560.67370.907-13.3517-7.4235-3.3313-2.5924-1.9513-5.0812-0.62170Partial curve; partial efficacy; poor fit-4.51371.62590.7426-35.2959-4-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.4966
Inactive10004-0.97-4.3623-1.46539.6687-8.1041-8.3111-5.9686-3.301-4.21888.9934-5.42630-0.6903-0.9710004-9.314
Inactive10004-1.4457-6.89480.2171-2.9459-4.0435-7.3456-1.1919-9.5752-2.6175-0.3368-10.17-0.6414-0.3902-1.445710004-2.246
Activator9.678780.70610004-5.3519-9.0236-6.6327-5.8557-0.1803-16.2183-5.9643-10.6841-5.3049-7.3617-3.4598-16.9691-11.695-5.35190Partial curve; high efficacy-5.01420.80.925776.7855-3.92052.10 0 0 0 0 0 1 0 0 0 0 0 0 0 075.366
Inactive10004-2.6023-5.1436-20.2543-4.2156-18.6587-1.1774-0.484-24.4038-1.4626-19.5587-5.8609-4.7343-6.9928-2.602310-4.16370.90.3781-32.45411.727340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2572
Inactive10-4.61370.90.4124-15.1446-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.347-0.3142-1.0420.9937-0.4332-5.17271.7846-9.5432-1.6937-2.2733-1.8768-12.2038-8.3511-0.347100041.5347
Inhibitor24.336570.80710004-0.78071.9061-0.7815-4.8851-12.66.6198-2.75363.05454.79781.16051.40111.6918-6.1939-0.78070Partial curve; partial efficacy-4.61371.69240.6988-64.3076.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-29.6108
Inactive10004-0.90493.2372.47662.64980.4207-1.39261.0889-11.66593.0536-1.96911.06293.9096-0.09-0.904910-6.26374.95490.42258.5-0.163240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.6214
Inactive10-4.66371.46410.3698-14.6386-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.0234-8.0187-2.80042.58961.4724-2.46990.0707-3.28221.0981-1.2965-10.7454-0.5498-16.3655-11.023410004-27.7999
Inactive10-6.56424.95490.44474.5-3.852440 0 0 0 0 0 0 0 0 0 0 0 0 0 05.6033-4.33852.27942.7066-14.0436-0.8758-9.51473.77765.08233.93465.49423.25690.88475.603310-6.76424.95490.3433-3.052140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.4886
Inhibitor18.49830.91151000413.22156.882221.7764.66487.65575.4813.49695.24837.72715.712213.43636.7754-1.020413.22150Partial curve; partial efficacy; poor fit-4.73294.95490.5896-30.65330.2582-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.5807
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC363
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197192 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.073 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 237.6 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.75414.95490.42033-4.98140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.9106-3.9228-5.9903-6.0515-1.4717-5.2912-7.602-5.9977-2.42-5.7364-8.2934-0.25662.9408-4.9106QC'd by SigmaAldrichInactive0
Inactive0004-3.3812-1.5662-16.55440.4975-4.09261.5304-12.9724-8.9269-1.91620.6198-11.0605-9.0324-13.3792-3.3812QC'd by SIGMAInactive0
Inactive00041.5277-10.1634-0.00874.0005-6.6661-6.69563.5741-1.09852.27453.2409-13.4326-7.2215-7.42071.5277QC'd by SigmaAldrichInactive0
Inactive0004-1.017-0.1246-23.0301-16.6405-6.1553-10.2548-6.5018-9.7542-2.401-3.4974.2117-8.21190.1193-1.017QC'd by SigmaAldrichInactive0-5.65984.95490.539
Inactive00043.38271.7071.93473.1752-3.8498-3.73072.23732.339-0.9899-3.4194-1.9669-9.73383.77663.3827QC'd by SIGMAInactive0
Inactive0004-0.73285.5587.8092.5786-0.96210.07372.9401-0.38870.14421.36820.83672.63761.7298-0.7328QC'd by SigmaAldrichInactive0
Inactive00042.35882.51021.81950.59232.94893.56280.6572-0.3826-0.85440.17520.73831.72051.81952.3588QC'd by Io-li-tecInactive0
Inactive00041.38781.00940.6532-1.03560.36512.28341.3107-16.37711.71522.1357-0.1164-0.65752.02321.3878QC'd by Io-li-tecInactive0
Inactive00045.46932.7258-1.71972.3804-20.79223.17021.6326-1.2539-13.72260.20822.47040.50210.58075.4693QC'd by SIGMAInactive0-5.85983.06540.6429
Inactive0-4.16644.0450.6851-12.45790.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.54830.2178-0.2309-0.79570.51171.13541.4003-0.03322.55783.2818-3.286-1.4703-0.7627-9.5483QC'd by SIGMAInactive0-4.36641.98870.8468
Inconclusive23.990430.144810Partial curve; partial efficacy; poor fit-4.620.70.747630-0.14482.40 0 0 0 0 0 0 0 0 0 0 0 0 0 022.60371.2906-5.817-1.8818-7.2041.07217.41797.545.08272.19837.159913.888719.365422.6037QC'd by SIGMAInactive0-4.120.50.4
Inactive00042.59482.69211.2072-3.7186-4.66812.76633.94650.38173.5477-0.23396.89892.65815.70112.5948QC'd by AcrosInactive0
Inactive0-4.19134.0450.813213-1.521440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5641-2.86591.25950.2725-1.1592-2.4294-2.1941.7532-2.4893-1.6357-0.1925-1.74781.073610.5641QC'd by SIGMAInactive0
Inactive00047.9141-1.9689-2.253-4.53782.2968-12.15473.36423.88694.99273.8103-8.57025.75174.7237.9141QC'd by SIGMAInactive0
Cytotoxic30.357783.203640Partial curve; high efficacy-4.51771.55790.9633-85.4248-2.2213-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.09710.1445-3.4687-6.33-5.4346-2.1394-5.5181-4.45781.539-0.7887-20.6233-25.9409-48.5781-79.0971QC'd by SIGMACytotoxic60.571591.352241Partial curve; high efficacy-4.21771.3310.9211
Inactive0-4.11374.95490.508311-1.19640 0 0 0 0 0 0 0 0 0 0 0 0 0 07.6371-0.9966-6.4133-1.62961.9829-2.5154-0.6080.0257-0.63170.3616-2.9777-3.0149-0.89117.6371QC'd by SIGMAInactive0
Cytotoxic69.777181.308620Single point of activity-4.15634.95490.9502-84.9425-3.6339-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.79571.365-8.0975-1.71050.6639-11.5921-1.7071-5.2425-4.18560.7387-7.358-7.5217-8.401-69.7957QC'd by SigmaAldrichCytotoxic69.777178.320620Single point of activity-4.15634.95490.9859
Inactive0004-13.1552-4.8346-4.34493.2135-7.58344.6528-8.09981.1002-3.0242.43910.6845-2.3657-3.4277-13.1552QC'd by SigmaAldrichInactive0-6.31074.95490.4218
Inactive0004-22.127-12.1698-7.5453-6.5016-5.9755-2.61933.5381-1.3673-14.7241-1.0064-4.7639-6.1963-2.5303-22.127QC'd by InterchemCytotoxic69.567322.86820Single point of activity-4.15764.95490.8014
Inactive0004-5.0254-5.9486-2.7845-5.6405-2.1794-5.01680.8851-0.4331-4.3384-8.3171-7.9408-6.7025-12.8316-5.0254QC'd by SigmaAldrichInactive0-7.15934.95490.3077
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Bile salt export pump
External ID: CHEMBL4011663
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Toxicol Sci
Year: 2010
Volume: 118
Issue: 2
First Page: 485
Last Page: 500
DOI: 10.1093/toxsci/kfq269

Target ChEMBL ID: CHEMBL6020
ChEMBL Target Name: Bile salt export pump
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
5.9IC50=5900nM
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
37.8IC50=37800nM
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range